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ABSTRACT 
 
SARAH C. GOETZ:  The Regulation of Cardiac Cell Proliferation and Survival During 
Vertebrate Development 
(Under the direction of Frank L. Conlon) 
 
The formation of organs during development requires that cell proliferation occur in a 
coordinated fashion.  Furthermore, mis-regulation of the cell cycle during adulthood is 
associated with cancer and other human diseases. The molecular pathways that govern the 
eukaryotic cell cycle have been extensively studied, however the mechanisms by which the 
cell cycle is regulated in a tissue specific manner during development are not well 
understood.  In this work, we explore the regulation of cell proliferation within the 
developing heart, as well as the maintenance of proliferating cardiac progenitor cells.   
The T-box transcription factor TBX5 is expressed within the developing heart and is 
required for heart morphogenesis in vertebrates.  Additionally, mutations to TBX5 have been 
associated with the human congenital heart defect Holt-Oram syndrome.  Despite the 
evolutionarily conserved role for TBX5 in heart development, the precise cellular 
requirement for TBX5 has not been defined.  We show that one of the earliest defects in the 
TBX5-depleted Xenopus embryos is a reduction in cardiac cell number due to a decrease in 
mitotic index.  We have further demonstrated that TBX5 is both necessary and sufficient to 
control cardiac cell cycle progression, and that depleting TBX5 leads to arrest in late G1 or 
iii
early S-phase of the cell cycle.  In this way, TBX5 is required to establish cardiac 
morphology during development. 
Finally we have identified a requirement for the tyrosine phosphatase SHP-2 in the 
maintenance of proliferating cardiac progenitor cells downstream of FGF signaling.  These 
studies show that SHP-2 is required for the maintenance of cardiac precursors, and that in the 
absence of SHP-2 activity, there is an increase in programmed cell death specifically in the 
cardiac precursor cells and pharyngeal mesoderm.  When SHP-2 activity is inhibited at a 
later stage, when many cells have exited the cell cycle, cardiac differentation is able to 
proceed, however the number of proliferating cells within the heart is substantially reduced.  
These data suggest a specific requirement for SHP-2 in the survival of proliferating cardiac 
progenitor cells.   
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CHAPTER 1 
Introduction 
 
During development, numerous processes, such as cell fate specification, proliferation, 
migration, and cell death, must occur in a coordinated fashion.  The failure of any of these 
processes during embryogenesis can lead to developmental abnormalities, while the mis-
regulation of many of the same pathways in adulthood is associated with disorders such as 
cancer.  Thus, understanding the cellular and molecular mechanisms of development 
provides crucial insight for human health. 
The mechanisms by which cell proliferation is regulated have been extensively studied in 
single celled eukaryotes such as yeast, as well as in cultured cells.  These studies have 
provided numerous valuable insights into how the different stages of the cell cycle are 
regulated, as well as the mechanisms by which cells exit the cell cycle and cease 
proliferating.   Comparatively less is known about developmental regulation of cell 
proliferation, and especially about how this is achieved in a tissue-specific manner.  A 
primary focus of my work has been on characterizing factors that promote cell cycle 
progression and cell survival specifically within the developing heart.
 
2General Mechanisms of Cell Cycle Control
The eukaryotic cell cycle is divided into four basic stages: M-phase in which mitosis occurs, 
S-phase in which DNA is synthesized for the next round of cell division, and two gap phases- 
G1, which proceeds S-phase, and G2, between S-phase and M-phase (Fig. 1.1).  The gap 
phases play regulatory roles, with the G1 restriction point acting to limit the rate at which 
cells proceed through the cell cycle, and ensure that cells have undergone cytokinesis prior to 
the initiation of DNA synthesis in S phase, while the G2 checkpoint assures that DNA is 
fully replicated prior to the onset of M-phase (Nurse, 1997).   
 The progression from one phase of the cell cycle to another is regulated primarily by 
the activity of cyclins and associated cyclin dependent kinases (CDK) (Sherr, 1993).  Cdks 
regulate the major transitions of the cell cycle by phosphorylation of their target proteins.  
The activity of Cdks is regulated in turn through their association with cyclins, which are 
present only at specific stages of the cell cycle.  To become catalytically active, Cdks first 
associate with a cyclin.  This in turn enables phosphorylation of the Cdk, which allows for 
the activation of its catalytic domain through conformational changes induced by the addition 
of the phosphate group (De Bondt et al., 1993; Russo et al., 1996).  During G1, progression 
of cells to S phase is mediated primarily by D, E, and A cyclins and their associated Cdks 
(Ekholm and Reed, 2000; Sherr, 1993).  Cyclin D/Cdk4/6 and Cyclin E/Cdk2 promote 
progression through the cell cycle primarily by acting sequentially to phosphorylate and 
inactivate retinoblastoma protein (Rb) (Harbour et al., 1999).  Active Rb acts as a 
transcriptional repressor, inhibiting expression of other factors required for cell cycle 
progression (Zhang et al., 2000).  In addition, Rb also binds to and sequesters members of the 
E2F family of transcription factors, and prevents their activating downstream targets that 
3function to promote cell cycle progression (Bagchi et al., 1991; Chellappan et al., 1991; 
Hiebert et al., 1992) (Fig. 1.2).   
 In addition to promoting entry into S-phase by inhibiting Rb, the G1 cyclin/Cdk 
complexes also promote the synthesis and activation of the licensing factors required for 
replication of the DNA during S-phase (Blow, 2001; D'Urso et al., 1990). Licensing occurs 
when the pre-replication complexes (RC) consisting of the origin recognition complex 
(ORC), Cdc6, Cdt1, and mini chromosome maintenance (MCM) proteins are loading onto 
the DNA.  The complexes are then activated by G1 cyclin/Cdk complexes including Cyclin 
E/Cdk2, allowing S phase of the cell cycle to begin (Blow, 2001; Takisawa et al., 2000).  
Replication of the DNA once and only once during each S phase is assured by the 
displacement of the MCM proteins from the pre-RC after origin firing, and also by 
subsequent activity of S-phase CDKs in mediating the displacement and degradation of the 
other pre-RC components (Nguyen et al., 2001).   
 In order to assure that faithful replication of the DNA has occurred prior to mitosis, 
cells undergo a DNA damage checkpoint in G1 prior to entry into S phase, and again in G2 
prior to M phase of the cell cycle (Elledge, 1996).  In this way, the gap phases of the cell 
cycle provide critical mechanisms for regulating both the length of the cell cycle and the 
frequency with which cells proliferate, and also assure that both daughter cells receive an 
intact genome.  Cyclin/CDK complexes also play key roles in these DNA replication 
checkpoints.  In response to DNA damage detected during G1, p53 is activated, and in turn 
activates transcription of p21, a cyclin dependent kinase inhibitor (CKI), which binds to 
CDKs, including Cdk4, and inhibits their activity (Elledge, 1996).  Thus cells are prevented 
from entering S phase in the presence of DNA damage (Fig. 1.2).  During S phase, DNA 
4replication can be slowed or stopped in response to DNA damage to allow time for repair to 
take place.  A final checkpoint during M phase assures that chromosomes are properly 
segregated to daughter cells prior to cytokinesis (Reviewed by (Rudner and Murray, 1996)).  
Cell Cycle Regulation During Development
Much of what is known about the regulation of the cell cycle and DNA synthesis has been 
studied primarily in yeast, mammalian cell culture, or in cell-free systems using Xenopus 
oocyte extracts (Chellappan et al., 1991; Cross, 1988; Lohka et al., 1988; Murray and 
Kirschner, 1989; Murray et al., 1989; Nurse, 1975).  During embryonic development, 
however, the cell cycle is modified by extracellular signaling events, with some cell types 
exiting the cell cycle early in development, while others proliferate extensively up to 
adulthood.  Studies to address the in vivo requirements for important cell cycle regulators 
during development have initially been carried out in Drosophila (Follette and O'Farrell, 
1997; Lehner and O'Farrell, 1990).   Drosophila provides and excellent model system for 
studying the developmental requirements for cell cycle regulators, as the Drosophila embryo 
initially undergoes synchronous rounds of DNA replication followed by nuclear cleavage, 
while the cytoplasm remains as a syncytium.  A G2 phase is then added once the embryo 
begins to cellularize after 13 rounds of replication, and later in development, a G1 phase is 
added (Orr-Weaver, 1994).  This increasing complexity of the cell cycle over the course of 
development made it possible to assess how cyclin/Cdk complexes are differentially 
regulated with the addition of the gap phases.   
Cyclins A and E, which were shown to promote cell cycle progression in yeast and in 
Xenopus oocyte extracts (Booher et al., 1989; Koff et al., 1991; Murray and Kirschner, 1989; 
5Murray et al., 1989), are both necessary and sufficient to trigger S phase in Drosophila 
embryos, and are thereby essential for embryonic development (Knoblich et al., 1994; 
Lehner and O'Farrell, 1990).  Both Cyclin A and E are regulated differently at distinct stages 
of development.  Cyclin A is expressed at fairly low levels at syncytial stages, with 
expression increasing with the addition of the G2 phase (Whitfield et al., 1990).  Cyclin E is 
expressed constitutively during the early stages of Drosophila development, when the 
embryo undergoes alternating rounds of S phase followed by nuclear cleavage without 
intervening gap phases (Richardson et al., 1993).  Upon the addition of G1 phase following 
cellularization, Cyclin E expression is downregulated (Duronio and O'Farrell, 1994; 
Knoblich et al., 1994), and its activity is further restricted by the expression of cell cycle 
inhibitors such as Decapo, the Drosophila homolog of vertebrate p27 (de Nooij et al., 1996; 
Lane et al., 1996).  Collectively, these early studies of cell cycle control in Drosophila 
demonstrated the critical role of cell proliferation in normal embryogenesis. 
More recently, studies have been undertaken in the mouse to determine the 
requirements for various cell cycle regulators during vertebrate embryonic development 
(Reviewed by (Sherr and Roberts, 2004)).   Surprisingly, despite the key role that 
cyclin/CDK complexes play during cell cycle progression, individual cyclins and CDKs 
largely do not appear to be required for embryonic development in mammals and other 
vertebrates (Berthet et al., 2003; Geng et al., 2003; Kozar et al., 2004; Malumbres et al., 
2004).  Targeted deletion in mice of Cyclin A2, which is required for both G1/S and G2/M 
transition, does result in early embryonic lethality.  Embryos are able to develop until mouse 
embryonic day (E) 5.5-6.5, however this is most likely due to the presence of cyclin A2 
6protein translated from maternal mRNA stores, which is depleted by E6.5 (Murphy et al., 
1997).    
In contrast to Cyclin A2, deletion of the G1 cyclins, Cyclin E1 and E2, does not result 
in early embryonic lethality or impaired cell cycle progression (Geng et al., 2003).  This is in 
contrast to Drosophila, where Cyclin E was required for progression to S phase, and its 
absence results in embryonic lethality.  Additionally, knockout of all three mammalian D 
Cyclins, Cyclins D1, D2, and D3, failed to cause widespread proliferation defects in mouse 
embryos (Kozar et al., 2004).  Triple knockout formed most tissues normally, and cells 
derived from these embryos were able to enter S phase.  The embryos display cardiac 
abnormalities, however, which likely results in the observed lethality between E13.5 and 
E15.5 (Kozar et al., 2004).  Similarly, mice lacking both Cdk4 and Cdk6, which partner with 
the D Cyclins to promote the initial phosphorylation of Rb, are viable until late stages of 
gestation.  Additionally, deletion of Cdk2 the binding partner of the E and A cyclins, does 
not result in major cell cycle defects in vivo (Ortega et al., 2003).  Only the combined 
knockout of Cdk2 and Cdk4 has been shown to result in defects in cell cycle progression and 
loss of Rb phosphorylation in vivo. However, these embryos survive until E15, and die 
primarily due to cardiac defects (Berthet et al., 2006). 
Together, these data suggest that a high level of functional compensation can occur 
between the different Cyclins and Cdks.  The lack of a severe phenotype in the Cdk4/Cdk6 
double knockout or the Cyclin D triple knockout suggests that Cdk2/Cyclin E can 
compensate for Cdk4/6/Cyclin D complexes to promote S phase entry, and vice versa.  
Functional redundancy between the G1 Cyclin/Cdks is further supported by the finding that a 
knock-in of Cyclin E into the Cyclin D1 locus is able to rescue the tissue-specific defects 
7resulting from the Cyclin D1 knockout (Geng et al., 1999).  The functional redundancy 
between the various cyclin/Cdk complexes is not total, however, as other complexes cannot 
fully compensate for the loss of both Cdk2 and Cdk4.  However, the fact that the embryos 
survive until E15, and there are fairly high levels of mitosis and Rb phosphorylation until 
mid-gestation, suggests that some degree of compensation occurs (Berthet et al., 2006). 
The unexpected degree of functional redundancy between the Cyclin/Cdk complexes 
in vivo compared with what has been observed in cell culture underscores the importance of 
understanding how the cell cycle is regulated during development.  Of particular interest is 
that, while knockouts of individual or various combinations of Cyclins and Cdks do not 
cause massive defects in cell proliferation throughout the embryo, deletion of each of these 
genes results in subtle and tissue specific defects.  For example, deletion of Cdk4 affects 
primarily pancreatic islet cells (Rane et al., 1999), while the loss of Cyclin E results in a 
failure of endoreplication in trophoblast giant cells (Geng et al., 2003), and deletion of 
Cyclins D1, D2, and D3 primarily affects heart and hematopoetic development (Kozar et al., 
2004).  This suggests that the relative roles of these cyclin/Cdk complexes, despite their 
broad expression patterns, might be somewhat tissue specific.  Thus, the examination of how 
the cell cycle is regulated in a tissue specific manner during development can provide 
important insights into organogenesis and is in need of further study.  
 
Overview of Vertebrate Heart Formation
In order to explore the regulation of cell proliferation during cardiac development, and the 
role of this process in ensuring the proper formation of the heart, it is necessary to give a 
brief overview of heart development in vertebrates.  In all vertebrate species, the heart is 
8among the first organs to form, and the basic processes of cardiac development are largely 
conserved across vertebrate species (Fishman and Chien, 1997).  Two bilateral populations of 
cells on either side of the midline of the embryo are induced into the cardiac lineage during 
gastrulation by signals emanating from the anterior endoderm underlying the anterior lateral 
plate mesoderm, and from the organizer (Jacobson and Duncan, 1968; Nascone and Mercola, 
1995; Sater and Jacobson, 1989; Schultheiss et al., 1995).  The position of cardiac cells along 
the anterior-posterior axis, which will ultimately determine which cardiac chamber they 
contribute to, is determined in part by the order in which they pass through the blastopore or 
primitive streak (Garcia-Martinez and Schoenwolf, 1993).  Additionally, the anterior portions 
of the heart tube, including the outflow tract and right ventricle, are contributed by the 
anterior heart field (Cai et al., 2003; Waldo et al., 2001).  The cells of the anterior heart field 
reside in the splanchic mesoderm anterior to the primary cardiac mesoderm, and express the 
marker islet1 (isl1) (Cai et al., 2003). 
Following induction, the two populations of cardiac precursors migrate to the midline 
of the embryo where they fuse and form the linear heart tube composed of both an outer 
myocardial layer which will form the beating heart muscle, and an inner endocardial layer, 
which will form the endothelial layer of the heart contiguous with the vasculature (Reviewed 
by (Fishman and Chien, 1997; Harvey, 2002)).  Once the bilaminar heart tube has formed, 
the heart begins the process of rightward looping, which will ultimately generate the distinct 
chambers of the heart (Taber et al., 1995)- two atria and two ventricles in mammals and 
birds, while amphibians have a three chambered heart with a single ventricle (Fig. 1.3). 
 During cardiac looping, the ventral portion of the heart tube rotates to form the outer 
curvature of the heart, with the dorsal side becoming the inner curvature (Christoffels et al., 
92000a).  The chambers of the myocardium form out of the outer curvature through a process 
of rapid cell proliferation and increase in cell size (Soufan et al., 2006), while the cells of the 
inner curvature become the non chamber myocardium of the atrio-ventricular canal (AVC) 
and outflow tract (OFT), which will play a role in the alignment and septation of the cardiac 
chambers (Christoffels et al., 2000a). 
 The early patterning of the myocardium (ie, the formation of the chamber vs. non 
chamber myocardium) is established, in part, by differential expression of cardiac 
transcription factors.  The T-box transcription factor Tbx5 is expressed in the atria, and left 
ventricle of mammals, and in the common ventricle of amphibians (Bruneau et al., 1999; 
Chapman et al., 1996).  TBX5 and the homeobox transcription factor NKX2.5 have been 
shown to synergistically interact to activate transcription of Atrial naturitic factor  (ANF) 
(Bruneau et al., 2001b; Hiroi et al., 2001), and each of these transcription factors is required 
for expression of ANF in vivo (Bruneau et al., 2001b; Lyons et al., 1995; Tanaka et al., 1999).   
ANF marks the future chamber myocardium during embryonic development, and is excluded 
from non-chamber myocardium, such as the AVC (Christoffels et al., 2000a).   ANF 
expression in the AVC is specifically inhibited by the transcriptional repressor TBX2, which 
competes with TBX5 to bind the T-Box- binding-element in the ANF promoter (Habets et 
al., 2002).  Tbx2 is expressed in a pattern complementary to that of ANF- expressed in the 
AVC and OFT, and is excluded from the chamber myocardium (Habets et al., 2002).  Within 
the chamber myocardium, Tbx2 is repressed by TBX20 (Cai et al., 2005; Singh et al., 2005; 
Stennard et al., 2005), another T-box transcription factor that promotes formation of cardiac 
chambers (Fig. 1.4).   
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Other chamber restricted cardiac transcription factors include Hand1 and Hand2 (also 
known as eHand and dHand, respectively).  In mammals, Hand1 and Hand2 are restricted to 
the left and right ventricles, respectively but are expressed ubiquitously in avian and 
amphibian hearts (Srivastava et al., 1995; Srivastava et al., 1997).  The Iroquois homeobox 
genes (Irx) are also expressed in specific cardiac chamber primoridia (Christoffels et al., 
2000b).  The mechanisms by which these chamber-specific transcription factors promote 
cardiac morphogenesis are just beginning to be understood.  Hand1, Hand2, and Irx4 have all 
been shown to be required for proper heart development, and for the expression of chamber-
specific markers (Bruneau et al., 2001a; Riley et al., 1998; Yamagishi et al., 2001).  However 
their precise cellular functions remain unknown.  The polarity of the heart tube seen through 
the differential expression patterns of these and other cardiac genes is later reinforced by 
changes in cell proliferation, polarity, and size (Christoffels et al., 2000b).  The roles of some 
of these transcription factors in cell proliferation will be further explored below. 
 
Regulation of Cell Proliferation During Early Cardiac Development
Cell proliferation plays a key role in heart formation.  Following the initial induction of 
cardiac precursor cells in vertebrate embryos, these cells undergo a period of rapid 
proliferation, corresponding with E8 in the mouse (Alsan and Schultheiss, 2002; Pasumarthi 
and Field, 2002; Schultheiss et al., 1995).  Proliferation within the heart field then transiently 
slows, followed by a second peak in proliferation at E11 (Pasumarthi and Field, 2002).  
However, the molecular mechanisms regulating these waves of proliferation within the 
precardiac mesoderm are poorly understood.   
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This early period of proliferation in the precardiac mesoderm corresponds with the 
close association between the endoderm and the cardiac progenitor population.  During this 
time, cardiac cells continue to be exposed to a variety of growth factors, including fibroblast 
growth factors (FGFs) and bone morphogenic proteins (BMPs).  In particular, Fgf8,
expressed in the endoderm contacting the precardiac mesoderm in chicks, is required for the 
maintenance of Nkx2.5 and Mef2c expression (Alsan and Schultheiss, 2002).  FGF signaling 
has also been implicated in cardiac cell proliferation specifically during this developmental 
window, with several studies demonstrating that FGFs 1, 2 and 4, which are expressed 
beginning at gastrulation (Hamberger-Hamilton stage 5 in chick) in the endoderm underlying 
the heart-forming field, are required for cardiac cell proliferation in explants of the precardiac 
mesoderm (Sugi et al., 1993; Zhu et al., 1999; Zhu et al., 1996).  Moreover, a retroviral 
vector encoding a dominant negative form of FGF receptor 1 (FGFR1) resulted in reduced 
cardiac cell proliferation when infected at day 3 and assessed at day 7 of chick development, 
demonstrating a requirement for FGF signaling in cardiac cell proliferation in vivo later in 
heart development.  In contrast, no effect on cardiac cell proliferation was observed when 
hearts were infected at day 7 and observed at day 14 (Mima et al., 1995).  Together these 
data suggest a role for FGF signaling in regulating the high levels of cardiac cell proliferation 
observed during the early stages of cardiac migration, heart tube formation, and cardiac 
looping (Pasumarthi and Field, 2002).  Moreover, the reduction in cardiac proliferation that 
occurs after stage 24 in chick (approx. E12 in mouse), corresponds closely with reduced 
expression of FGFs within the myocardium (Zhu et al., 1996). 
BMPs are also present in the early heart field and myocardium during the same 
developmental window as FGFs.  Together with FGF signaling, BMP signaling also plays a 
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role in the induction and maintenance of early cardiac progenitor cells (Lough and Sugi, 
2000).   BMP2, expressed in the anterior endoderm, is required for the induction of cardiac 
progenitors in early heartfield explants (Schultheiss et al., 1997), and together with FGF4, is 
sufficient to induce non-cardiac mesoderm to produce heart tissue (Lough et al., 1996).  
Recent evidence also suggests that FGF/MAPK signaling may counterbalance BMP 
signaling in vivo. Smad1 is a key effector of the BMP pathway that is activated by 
phosphorylation in response to BMP signaling.  Smad1 then translocates to the nucleus 
where it activates transcription of downstream targets of the BMP pathway.  Smad1 is also 
phophorylated by MAPK within the linker domain connecting the DNA binding and 
membrane receptor binding domains.  This MAPK-mediated phosphorylation restricts 
Smad1 activity by promoting its recognition by the ubiquitin ligase Smurf1.  Subsequently, 
Smad1 is prevented from entering the nucleus, and targeted for degradation by the 
proteasome (Sapkota et al., 2007).  Thus, FGF/MAPK signaling can act to negatively 
regulate BMP signaling in certain cellular contexts.  
BMP signaling downstream of Gata6 also appears to be required after the initial 
induction of cardiac progenitors for the maintenance of early cardiac genes, including Nkx2.5 
(Peterkin et al., 2003).  Later in development, BMPs function to promote the proliferation of 
the myocardium, as mice lacking BMP receptor 1A exhibit a thin myocardial wall (Gaussin 
et al., 2002), while mice lacking the BMP antagonist Noggin display hyperplastic growth of 
the ventricular myocardium (Choi et al., 2007).      
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Proliferation and Cardiac Morphogenesis
In spite of the reduction in cell proliferation that occurs during cardiac chamber formation 
and remodeling, cell proliferation plays a critical role throughout the process of heart 
morphogenesis.  The initially high levels of DNA synthesis observed in the early pre-cardiac 
mesoderm and myocardium are thought to be important both for the expansion and 
segmentation of the heart tube along its anterior-posterior axis, as well as for the formation of 
the cardiac chambers (Christoffels et al., 2000a; Soufan et al., 2006).  
Recent studies of the basic-helix-loop-helix transcription factor Hand1 underscore the 
importance of proper regulation of the cardiac cell cycle in heart morphogenesis.  Loss of 
function and over-expression studies support a role for Hand 1 in promoting the proliferation 
of cardiac progenitor cells prior to terminal differentiation (McFadden et al., 2005; Riley et 
al., 1998; Risebro et al., 2006).  Deletion of Hand1 from the developing heart results in 
shortening of the outflow tract as well as hypoplasia of the right ventricle, resulting in the 
formation of an unlooped heart tube (Riley et al., 1998).  In contrast, over-expression of 
Hand1 within the developing heart tube has the opposite effect where the outflow tract is 
lengthened due to increased cell proliferation, resulting in abnormal cardiac looping (Risebro 
et al., 2006).  Thus, the proliferation of cardiac precursor cells plays a role in establishing the 
correct length of the early heart tube, thereby contributing to the process of cardiac looping. 
In addition to playing a crucial role in establishing the length of the heart tube, 
increased levels of cell proliferation are observed in the presumptive chamber myocardium of 
the atria and ventricles, as compared with the non-chamber myocardium of the OFT and 
AVC (Christoffels et al., 2000a).  The mechanisms by which cell proliferation is 
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differentially regulated between the chamber myocardium and non-chamber myocardium are 
not well characterized, however some recent studies have begun to elucidate this process.   
The early cardiac chambers of the vertebrate heart are initially formed by increased 
levels of proliferation in the presumptive chamber myocardium compared with non-chamber 
myocardium of the heart tube.  This results in the “ballooning” out of the chamber 
myocardium (Christoffels et al., 2000a; Soufan et al., 2006).  Prior to this expansion, 
chambers are specified in part by the activity of cardiac T-Box transcription factors.  Tbx5 
exhibits a graded expression pattern within the heart tube, with the highest levels of 
expression seen in the future atria and left ventricle (common ventricle in amphibians) 
(Christoffels et al., 2000a; Horb and Thomsen, 1999), while Tbx20 is expressed throughout 
the developing myocardium (Brown et al., 2003; Iio et al., 2001; Kraus et al., 2001).  These 
two transcription factors promote the formation of the chamber myocardium in concert with 
NKX2.5 by promoting expression of chamber-specific genes.  In the non-chamber 
myocardium, the activity of TBX5 and TBX20 is opposed by the transcriptional repressors 
TBX2 and TBX3 (Christoffels et al., 2004), which are thought to compete for binding to 
NKX2.5 (Habets et al., 2002).   Furthermore, TBX20 has been shown to repress Tbx2 
expression within the chamber myocardium: in the absence of TBX20, Tbx2 expression is 
increased throughout the heart tube (Cai et al., 2005).  Interestingly, TBX2 has been shown 
to repress transcription of N-myc, a protein required for G1/S transition in cardiac and other 
cell types (Moens et al., 1993).  Deletion of Tbx20 thereby results in decreased expression of 
N-myc and hypoplasia of the heart and a failure of cardiac morphogenesis (Cai et al., 2005).  
These data support a model of chamber formation wherein, cell proliferation is maintained at 
low levels in the non-chamber myocardium, while high levels of proliferation are promoted 
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in the chamber myocardium, either by repressing the activity of factors that inhibit cell cycle 
progression, or by directly promoting cell cycle progression (Fig. 1.4). 
 In addition to a role in chamber formation, cardiac cell proliferation is also important 
for the remodeling of the ventricles to distinguish the compact and trabecular myocardium.  
Remodeling of the ventricles begins at the end of the cardiac looping stage (E10.5 in mouse, 
HH stage 18 in chick, and Niewkoop and Faber stage 37 in Xenopus).  The trabeculae of the 
ventricle are finger-like bundles of cardiomyoctyes that project into the chamber of the 
ventricle by about E10.5 in mouse.  In contrast, the compact myocardium consists of cardiac 
myocytes that are more densely organized.  In early embryonic heart function, the trabecular 
myocardium provides most of the contractile force, while later in heart development this role 
shifts to the compact myocardium (Sedmera and Thomas, 1996).  In addition to distinct 
cellular organization, the two myocardial layers also differ in their mitotic activity, with the 
compact myocardium being more highly proliferative, thereby driving the growth of the 
embryonic heart, and the trabecular myocardium proliferating at a much lower rate.  The 
mitotic index (MI) of the trabecular layer peaks at mouse E10.5, while in the compact layer, 
the MI peaks between E9.5 and E11.5 and gradually declines (Toyoda et al., 2003).   
 The fate of ventricular cardiomyocytes to become either compact or trabecular 
myocardium appears to be governed, at least in part, by signals emanating from the 
epicardium (Kang and Sucov, 2005; Lavine et al., 2005; Pennisi et al., 2003) and 
endocardium respectively (Gassmann et al., 1995; Kang and Sucov, 2005; Lee et al., 1995; 
Meyer and Birchmeier, 1995).   While the exact nature of the signal from the epicardium that 
patterns the compact myocardium is unknown (Kang and Sucov, 2005), the growth factor 
neuregulin plays a critical role in the outgrowth of the trabecular myocardium (Gassmann et 
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al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995).  Once this patterning is established, 
it is reinforced by the differential levels of proliferation observed between the compact and 
trabecular myocardium.  Proliferation in the compact myocardium is promoted primarily 
through FGF signaling downstream of retinoic acid from the epicardium (Lavine et al., 
2005).  Recently, several transcription factors have been identified that play crucial roles in 
cardiac morphogenesis by negatively regulating proliferation in the trabecular myocardium. 
 The gene jumonji (jmj), which encodes a member of the AT-rich interaction domain 
(ARID) family of transcription factors, was found to negatively regulate the cell cycle with 
over proliferation observed in hearts of embryos lacking jmj (Takeuchi et al., 1999).  The 
timing of jmj expression in trabecular and compact myocardium of the ventricle matches the 
time points when each begin to reduce their respective MI (Toyoda et al., 2003).  JMJ has 
been shown to function in part by repressing cyclin D1 expression in the trabecular 
myocardium (Toyoda et al., 2003).  JMJ also physically interacts both with NKX2.5 and 
GATA4.  This results in repression of ANF in the AVC (Kim et al., 2004), suggesting that  
JMJ plays a role in chamber formation beyond its function in regulating cell cycle 
progression.   
 Other transcription factors that act to restrict cardiac cell proliferation within the 
ventricular trabeculae include FoxP1, a member of the winged helix family of transcription 
factors (Wang et al., 2004), and HOP1, an unusual homeobox-containing protein (Chen et al., 
2002; Shin et al., 2002).  An increase in cell proliferation in the trabecular zone of Foxp1 null 
embryos has been observed, however, Foxp1 is expressed primarily in the compact 
myocardium and the mechanism by which Foxp1 acts to restrict proliferation in the 
trabeculae has not been established (Wang et al., 2004).  The hearts of HOP1 null mice 
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exhibit thickened ventricular walls in comparison with wild-type littermates, due primarily to 
an increase in cell number.  HOP1 appears to be expressed primarily within the trabecular 
myocardium of the ventricle, and was shown to physically interact with Serum Response 
Factor (SRF).  One molecular function of HOP1 is to antagonize the activity of SRF (Chen et 
al., 2002; Shin et al., 2002).  Again, the exact molecular mechanism by which HOP1 acts to 
inhibit cardiac cell cycle progression is not yet known.  Thus, analysis of how tissue-specific 
transcription factors interact with, and regulate the cell cycle machinery during development 
is crucial to our understanding of how specific organs are patterned, and achieve their 
required size and function. 
 In addition to differential rates of proliferation within the myocardium, recent 
analysis suggests that the orientation of cell divisions plays an important role in cardiac 
morphogenesis.  Retrospective clonal analysis of the developing mammalian heart has 
revealed two distinct phases of myocardial proliferation.  In the first phase, which 
corresponds to the formation and elongation of the heart tube earlier in development (prior to 
E8.5), descendents of individual labeled cells are observed to disperse over fairly long 
ranges, and always in along the arterio-venous axis.  Thus, this phase is termed the dispersive 
phase (Meilhac et al., 2003).  In the second phase, which begins at or around E8.5, clonal 
cells form larger clusters and remain adjacent.  This latter phase has been termed the coherent 
phase of growth, and further analysis revealed that coherent clones have a distinct orientation 
of growth that corresponds with the chamber in which they reside (Meilhac et al., 2003).  For 
example, clones in the outflow tract take on a linear anterior-posterior orientation, while 
clones in the left ventricle tend to radiate out away from the AVC (Meilhac et al., 2004; 
Meilhac et al., 2003).   This work provides evidence that the orientation of cell proliferation, 
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as well as the rate of proliferation, plays a critical role in cardiac morphogenesis.  In further 
support of this, several zebrafish mutants have been identified that have severe cardiac 
abnormalities due to the failure of cardiac cells to divide along the proper axis.  The mutants 
Santa, Valentine, and heart of glass each have a very similar phenotype wherein the hearts 
are enlarged, and exhibit a thin ventricular wall due to the failure to add concentric layers to 
the myocardium.  These concentric layers are added when cardiac cells shift their orientation 
of cell division to divide along the transmural axis (from the epicardium to the endocardium).  
Failure of this process results in expansion of the myocardium only along the initial axis 
(Mably et al., 2006; Mably et al., 2003).  Thus, cell proliferation within the heart plays a 
critical role in generating proper morphology and function of this organ. 
 
The Relationship Between Proliferation and Cardiac Differentiation
In many tissues, such as muscle, and the nervous system, the withdrawal of cells from the 
cell cycle is tightly associated with the onset of terminal differentiation (Alexiades and 
Cepko, 1996; Dyer and Cepko, 2001; Lathrop et al., 1985; Walsh and Perlman, 1997).  In 
contrast, relatively little is know about the relationship between the cell cycle progression 
and terminal differentiation in the heart.  Cardiac cells continue to proliferate until just after 
birth in mammals, when they finally exit the cell cycle.  As a result of this cell cycle exit, 
cardiomyocytes in the adult heart are very limited in their regenerative capacity.  In skeletal 
muscle, in contrast, associated muscle progenitor cells, satellite cells, retain the ability to 
proliferate and differentiate into mature muscle upon injury (Charge and Rudnicki, 2004). 
Mutations to a number of genes that are required for cell cycle progression in the 
heart also result in defects in cardiac differentiation.  Hand1 is required, primarily in the OFT 
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and left ventricle, for cell cycle progression at the G1/S transition by promoting transcription 
of cyclin D2 and Cdk4 (Risebro et al., 2006).  Over-expression of Hand 1 in the developing 
heart results in increased cardiac cell proliferation as well as delayed and reduced expression 
of cardiac differentiation markers (Risebro et al., 2006).  In addition, deletion of Jumonji, a
transcription factor that promotes cell cycle exit by repressing cyclin D1 expression (Toyoda 
et al., 2003), results in reduced expression of cardiac differentiation markers as well as 
increased proliferation within the heart (Takeuchi et al., 1999).  These experiments would 
lend support to a model where cardiac cell cycle exit and terminal differentiation are closely 
associated, inter-regulated processes, as has been demonstrated for other cell types.  
However, the consequences of disrupting the cell cycle upon cardiomyocyte differentiation 
during development have never been directly examined, leaving open the possibility that cell 
cycle exit is not directly linked with terminal differentiation with in the heart.  Supporting 
this possibility is the fact that cell proliferation continues within the heart even after the fully 
differentiated, beating heart has formed (Pasumarthi and Field, 2002). 
During development, cell proliferation in the heart continues at fairly high levels, 
even as cardiomyocytes begin undergoing terminal differentiation (Pasumarthi and Field, 
2002).  It is not clear, however, whether differentiated cardiomyocytes (ie, those that are 
expressing contractile proteins organized into sarcomeric structures) continue to proliferate, 
or whether a separate population of cells within the heart, such as undifferentiated progenitor 
cells or less differentiated cardiomyocytes, proliferate while terminally differentiated 
cardiomyocytes exit the cell cycle. 
Recently, several reports have indicated that rare cardiac progenitor cells exist within 
the mammalian myocardium.  These progenitor populations are positive for distinct sets of 
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markers, and were isolated from hearts at different stages, including embryonic, neonatal, 
and adult hearts  (Beltrami et al., 2003; Laugwitz et al., 2005; Moretti et al., 2006; Oh et al., 
2004; Wu et al., 2006).  One population of progenitor cells isolated from embryonic hearts 
and positive for islet1, a marker of progenitor cells originating from the secondary heart field 
during embryonic development, is capable of forming fully differentiated cardiomyocytes in 
culture (Laugwitz et al., 2005), and these cells are also capable of differentiating into 
endothelial and smooth muscle cells (Moretti et al., 2006).  cKit+ cells with the ability to 
differentiate into cardiac cells have been identified both in adult (Beltrami et al., 2003) and 
embryonic (Wu et al., 2006) hearts.  Finally, a Sca1+ population of cells in the adult 
myocardium are also capable of differentiating into cardiomyocytes when isolated from the 
heart and cultured in vitro, and also when injected back into mice with ischemia/reprofusion 
injuries (Oh et al., 2004).  Thus, despite the fact that cardiomyocytes begin to exit the cell 
cycle during embryonic development following the onset of differentiation, and that most 
cardiac exit the cell cycle shortly after birth, one or more populations of undifferentiated 
cardiac progenitor cells exist in both the embryonic and adult myocardium.  However, the 
molecular pathways by which these cells are specified and maintained within the heart during 
development are largely unknown. 
The fact that there are sub-populations of undifferentiated progenitor cells within the 
adult heart potentially lends support to a model wherein a separate population of cells within 
the heart continues proliferating during embryonic development as other cardiac cells 
undergo terminal differentiation.  It remains possible, however that this population of 
progenitor cells, which potentially represents an adult cardiac stem cell population, is set 
aside later in development, and is therefore distinct from the cardiac precursor cells during 
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embryonic development.  Therefore, a model wherein cardiac cells continue to proliferate as 
they proceed to differentiate cannot be excluded.  It has been demonstrated, for example, that 
differentiated cardiomyoctyes continue to undergo DNA replication, as shown by 
incorporation of BrDU (Armstrong et al., 2000).  However, this may be indicative of the 
round of endoreplication that is known to occur in post-mitotic cardiomyocytes (Armstrong 
et al., 2000; Pasumarthi and Field, 2002).   
 
Thesis Goals
Understanding the mechanisms by which the cardiac cell cycle is regulated during 
development can provide crucial insights into the molecular basis of congenital heart disease.  
In this work, I explore the requirements for the T-Box transcription factors TBX5 and 
TBX20 in heart development in the frog Xenopus laevis. In particular, I describe the role of 
TBX5 in promoting cell cycle progression within the heart during the developmental period 
corresponding with cardiac looping and chamber formation.  Finally, I will describe the 
requirement for the protein tyrosine phosphatase SHP-2 down stream of FGF signaling in the 
survival of proliferating cardiac progenitor cells.  In this way, we have gained a further 
understanding of how cardiac cell proliferation and survival are regulated and coordinated 
during vertebrate heart development.       
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Figure 1.1. The stages of the eukaryotic cell cycle.
The schematic depictes the stages of the cell cycle, mitosis (M), the first gap phase (G1), 
DNA synthesis phase (S), and the second gap phase (G2).  The predominant cyclin/Cdk 
complexes associated with each phase are also shown. 
23
Figure 1.2. Molecular mechanism of the G1/S transition.
A schematic of the major molecular pathways both promoting and inhibiting the progression 
to S phase of the cell cycle.  Growth factors promote entry into S phase by inducing 
expression and activity of Cyclin D, Cyclin E, and their associated Cdks.  These complexes 
in turn phosphorylate and inactivate the retinoblastoma protein (Rb), which then releases 
E2F, a transcription factor upstream of many other cell cycle promoting factors, as well as 
DNA replication factors.  Cell cycle progression can be inhibited by growth inhibitory 
signals, or by DNA damage, which results in p53 expression.  Both of these pathways result 
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in increased expression of Cdk inhibitors such as p21 and p27, which antagonize activity of 
the Cyclin/Cdk complexes, inhibiting entry into S-phase. 
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Figure 1.3. Development of the vertebrate heart.
A schematic depiction of the vertebrate heart morphogenesis (based on the mouse) at the 
equivalent of mouse E7.5 (A), E8.5 (B), E9.5 (C), and E11.5 (D).  The shaded regions in A 
are contributed by the anterior heart field in mammals and birds.  OFT = outflow tract, RV = 
right ventricle, LV= left ventricle, A = atria, AO = aorta, SV = sinus venosus, RA = right 
atrium, LA = left atrium.    
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Figure 1.4. T-box transcription factors and the development of the chamber and non-
chamber myocardium.
In the non-chamber myocardium (orange), TBX2 represses transcription of ANF and other 
genes specific to the chamber myocardium.  TBX2 also represses N-myc, a transcription 
factor that promotes cell proliferation, keeping proliferation levels low in the non-chamber 
myocardium.  In the chamber myocardium (red), TBX2 is displaced from binding to NKX2.5  
by TBX5, which in turn binds to the ANF promoter and  promotes its transcription.  In 
addition, expression of TBX2 is repressed by TBX20, thus relieving repression of N-myc.  
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This leads to higher levels of cell proliferation within the chamber myocardium.  OFT = 
outflow tract, IC = inner curvature, V = ventricles, A = atria. 
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CHAPTER 2
Tbx5 and Tbx20 Act Synergistically to Control Vertebrate 
Heart Morphogenesis 
 
PREFACE TO CHAPTER 2
Chapter 2 describes the requirement for the T-Box transcription factor TBX20 during 
vertebrate heart development, as well as providing evidence for a synergistic interaction 
between TBX20 and TBX5.  TBX20 had been previously shown to be expressed throughout 
the developing heart in mouse, avian, and Xenopus embryos (Iio et al., 2001; Kraus et al., 
2001; Brown et al., 2003), however a requirement for TBX20 in heart formation had not been 
demonstrated.   
 This work was published in Development in 2005 and produced in collaboration with 
Daniel Brown, Shauna Martz, Olav Binder, Brenda Price, and Jim Smith.  I performed the 
analysis of total cardiac cell number in embryos depleted of TBX5 and TBX20 by 
morpholinos.  The finding that there are fewer cells in the hearts of TBX5 and TBX20- 
depleted embryos also lead to the hypothesis that these transcription factors might be 
required for proliferation in the embryonic heart.  We test this hypothesis with respect to 
TBX5 in Chapter 4.   
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SUMMARY
Members of the T-box family of proteins play a fundamental role in patterning the
developing vertebrate heart; however, the precise cellular requirements for any one
family member and the mechanism by which individual T-box genes function remains
largely unknown. In this study, we investigate the cellular and molecular relationship
between two T-box genes, Tbx5 and Tbx20. We demonstrate that blocking Tbx5 or
Tbx20 gives phenotypes that display a high degree of similarity as judged by overall
gross morphology, molecular marker analysis, and cardiac physiology, implying that
the two genes are required for and have non-redundant functions in early heart
development. In addition, we demonstrate that although coexpressed, Tbx5 and Tbx20
are not dependent on one another’s expression, but rather have a synergistic role
during early heart development. Consistent with this proposal, we show that TBX5 and
TBX20 can physically interact, map the interaction domains, show a cellular interaction
for the two proteins in cardiac development and therefore, provide the first evidence for
direct interaction between members of the T-box gene family.
INTRODUCTION
The vertebrate heart constitutes the earliest functional organ in the developing embryo and
about 1% of all live births exhibit congenital heart disease (Hoffman, 1995a; Hoffman,
1995b; Payne et al., 1995). It is becoming increasingly clear that a complex molecular
regulatory network is required to initiate and complete the formation of a functional heart.
The proteins implicated in this process include a number of transcription factors from a range
of transcription factor families, including the T-box, basic helix-loop-helix homeodomain,
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zinc finger, and MADS domain families (Cripps and Olson, 2002; Harvey, 2002; Zaffran and
Frasch, 2002).
The T-box family of transcription factors is a large family of proteins involved in
determining early cell fate decisions and controlling differentiation and organogenesis. Two
sets of clinical data have provided direct evidence for the involvement of T-box genes in
human heart development (for review see Packham and Brook, 2003; Ryan and Chin, 2003).
Deletions of Tbx1 have been found in patients with DiGeorge syndrome (Baldini, 2004;
Chieffo et al., 1997; Jerome and Papaioannou, 2001; Lindsey et al., 2001; Merscher et al.,
2001; Yagi et al., 2003), and mutations in Tbx5 are associated with Holt-Oram Syndrome
(HOS), a congenital heart disease characterized by defects in heart formation and upper limb
development (Basson et al., 1997; Li et al., 1997). Clinical studies of HOS patients have
demonstrated a fundamental role for Tbx5 in heart development. HOS is a highly penetrant
autosomal dominant condition associated with skeletal and cardiac malformations (Newbury-
Ecob et al., 1996). Patients with HOS often carry mutations within the coding region of the
T-box transcription factor Tbx5 (Basson et al., 1997; Basson et al., 1999; Benson et al., 1996;
Li et al., 1997). The role of Tbx5 in heart development, and in the HOS disease state, is further
supported by recent gene-targeting experiments in mouse. These studies demonstrate that mice
heterozygous for mutations in Tbx5 display many of the phenotypic abnormalities of HOS
patients (Bruneau et al., 2001) and show that TBX5 is required for growth and differentiation
of the left ventricle and atria as well as for proper development of the cardiac conduction
system. Similar defects are seen in the zebrafish Tbx5 mutant heartstrings, suggesting that
the expression and function of TBX5 is conserved throughout vertebrate evolution (Garrity et
al., 2002).
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Previously, we described the cloning and expression of the Xenopus laevis (X. laevis)
Tbx20 orthologue, Tbx20 (Brown et al., 2003). Studies of Tbx20 have demonstrated that
along with Tbx5, Tbx20 is one of the first genes expressed in the vertebrate cardiac lineage.
Moreover, Tbx20 is expressed at the same time and in many of the same regions of the heart
that also express the heart markers Tbx5, Nkx2-5, and Gata4 (Horb and Thomsen, 1999;
Laverriere et al., 1994; Serbedzija et al., 1998; Tonissen et al., 1994).
Despite our knowledge of the expression pattern of Tbx20, little is known of Tbx20
function in heart development. In the zebrafish, it has recently been observed that eliminating
endogenous TBX20 (HrT) via morpholinos leads to cardiac defects (Szeto et al., 2002).
Specifically, TBX20 knockdown in zebrafish leads to dysmorphic hearts and a loss of blood
circulation. The morphological defects are not apparent until the cardiac looping stage,
despite high levels of Tbx20 during the earlier stages of specification and development
suggesting that other T-box genes may act redundantly with Tbx20 during early heart
development.
In this study we investigate the cellular and molecular relationship between Tbx5 and
Tbx20 in X. laevis. We show that the phenotypes of knocking down TBX5 and TBX20 are
highly similar, with embryos derived from either Tbx5 or Tbx20 morpholino injections
displaying profound morphological defects including pericardial edema, reduced cardiac
mass, and loss of circulation. In addition, we show that the morphological phenotype is not a
reflection of alterations in the specification, commitment, or differentiation of cardiac tissue.
Thus, in addition to sharing a number of molecular properties, we show that Tbx5 and Tbx20
function in a non-redundant fashion and are essential for cardiac morphogenesis. However,
despite the similarities in phenotype and shared molecular properties, Tbx5 and Tbx20 also
have independent roles in heart development.
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Given the similarity in TBX5 and TBX20 morphant phenotypes, we investigated the
pathways by which Tbx5 and Tbx20 function. We show that TBX5 and TBX20 do not
function in a linear pathway (i.e. Tbx20 does not act downstream of Tbx5, and vice versa),
but rather imply a synergistic role for these two proteins during early heart development.
Consistent with this proposal, we show that TBX5 and TBX20 can physically interact, map
the interaction domains, and show an interaction for the two proteins in cardiac development,
therefore providing the first evidence for interaction between members of the T-box gene
family.
MATERIALS AND METHODS
DNA Constructs 
XANF was generously provided by Paul Krieg (pXANF) (Small and Krieg, 2000), and the
cardiac troponin I (pXTnIc) plasmid was generously provided by Tim Mohun (Logan and
Mohun, 1993). Nkx2-5 was cloned by degenerate PCR from a ventral-anterior X. laevis
cDNA library (generous gift of Tim Mohun). Sequence analysis revealed that the clone
shows extensive homology to a partial sequence of the second X. laevis allele of Nkx2-5 
(accession AF283102). The clone is predicted to be full-length and in vitro translation of the
protein gave a band of the correct size. The clone is referred to as pCRNkx-2.5B (accession
number AY644403). To construct the pBS-Nkx2-5 hybridization probe, Nkx2-5 was
subcloned into pBLUESCRIPT II KS+. Details of XTbx20 and XTbx5, respective deletions
and GST fusions, cell transfections and nuclear localization protocols can be obtained at:
www.unc.edu/~fconlon/SuppMat.pdf.
Transient Transfections 
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293T cells were plated at 1 X 106 cells/well in six-well tissue culture plates 24 hours prior to
transfection. Plasmids used in transients are: the Nppa promoter-luciferase reporter (Hiroi et
al., 2001), pTbx5-V5, pTbx20-V5, pCMV-LacZ; pBS/KS. The amount of luciferase reporter
plasmid DNA was kept constant at 100 ng for Tbx5, while titering in Tbx20 (25 ng-100 ng).
Expression vector plasmid DNA was kept constant at 100 ng total and 50 ng of LacZ reporter
plasmid was used. Total amount of DNA was kept constant at 2 µg and transfected using
Lipofectamine 2000 (Invitrogen). Plasmid DNA was diluted in OPTI-MEM (GibcoBRL)
and complexes were allowed to form for 25 minutes at RT and added to each well. 48 hours
post-transfection, cells were harvested using M-PER (Pierce) with gentle shaking.
Luciferase activity was normalized to ß-galactosidase activity. All assays were done three
independent times in triplicate. Results were graphed using normalized Relative Luciferase
Units (RLUs).
Embryo Injections  
Preparation and injection of X. laevis embryos was carried out as previously described
(Wilson and Hemmati-Brivanlou, 1995). Embryos were staged according to Nieuwkoop and
Faber (Nieuwkoop and Faber, 1967). Equal amounts of both Tbx5 morpholinos were used in
all injections. This combination is referred to in the text and figures as “TBX5MO”. Tbx20
morpholinos were also injected in combination, and referred to as “TBX20MO”. TBX5MO
was injected at the optimal (40 ng) or suboptimal (20 ng) doses, and TBX20MO was injected
at the optimal (80 ng) or suboptimal (40 ng) doses. “Optimal dose” is defined as the dose
empirically found to be efficient at blocking protein translation both in vitro and in vivo, and
inducing a cardiac phenotype in nearly 100% of injected embryos, while “suboptimal dose”
refers to the dose empirically found to be below the threshold of the full cardiac phenotype-
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inducing dose. Sequence and details of morpholino oligonucleotides can be found at:
www.unc.edu/~fconlon/SuppMat.pdf.
Whole-mount RNA in situ hybridization 
Whole-mount in situ hybridizations were performed as previously described (Harland, 1991).
Embryos were cleared using 2:1 benzyl benzoate/benzyl alcohol (Sigma) (Figs. 5 and 9).
Immunohistochemistry 
Embryos were collected and fixed for 2 hours at 4 ºC in 4% paraformaldehyde and rinsed in
PBS, incubated overnight in 30% sucrose in PBS at 4 ºC, mounted in OCT cryosectioning
medium (Tissue Tek) and snap frozen. Cryostat sections (14um) sections were rinsed with
wash buffer (PBS, 1% Triton, 1% serum), incubated at 4°C overnight with anti-tropomyosin
(1:50; Developmental Studies Hybridoma Bank) (Kolker et al., 2000), and phalloidin
conjugated to Alexa 488 flourophore (Molecular Probes). Sections were then rinsed with
wash buffer and incubated with anti-mouse Cy3-conjugated secondary antibody (1:200),
(Sigma). Sections were rinsed and incubated for 20 minutes at RT with DAPI, cover slipped
and visualized on a Zeiss LSM410 confocal microscope.
Translation Inhibition by Morpholinos 
In vitro translations were performed using TNT® Coupled Reticulocyte Lysate System
(Promega) following the manufacturer’s protocol. Western protocol and antibody
information can be obtained at: www.unc.edu/~fconlon/SuppMat.pdf. We have recently
demonstrated that X. laevis SHP-2 is uniformly expressed throughout early development (Y.
Langdon and FLC, unpublished data) and was used as a loading control (1:2500)
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(Transduction Laboratories) with peroxidase-conjugated AffiniPure donkey anti-mouse
(H+L) secondary antibody (1:10,000). For in vivo translation analyses, embryos were
injected with MOs and mRNA at the one-cell stage and animal caps cut at stage 8. At sibling
stage 10, and 10 animal caps per treatment were collected and lysed in 100 µl of lysis buffer:
200 mM NaCl, 20 mM NaF, 50 mM Tris pH 7.5, 5 mM EDTA, 1% IGEPAL, 1% Triton X-
100 (Sigma), Complete EDTA-free Protease Inhibitor (Roche). Lysates were resolved on
12% SDS-PAGE gels, and visualization was carried out using Western Lightning
Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, Inc.).
Glutathione-S-Transferase Pulldown Assays 
GST pulldown assays were performed using the MicroSpin GST Purification Module
(Amersham Biosciences) according to the manufacturer’s protocol. Hemagglutinin (HA)-
tagged putative interacting proteins were produced in 293T cells
(www.unc.edu/~fconlon/SuppMat.pdf). Lysates were sonicated 3 times for 10 seconds prior
to centrifugation at 12,000 rpm at 4°C for 10 minutes, and the supernatant was collected.
GST-fusion protein lysates and putative interacting protein lysates were loaded on GST
columns, incubated for 1.5 hours at 25°C, eluted, electrophoresed on a 12% SDS-PAGE gel,
and transferred to PolyScreen PVDF Transfer Membranes. HA-tagged proteins were detected
with mouse HA.11 primary antibody (1:1,000, Covance Research Products) and with
peroxidase-conjugated AffiniPure donkey anti-mouse (H+L) secondary antibody (1:10,000).
GST-fusion proteins were detected with rabbit anti-GST primary antibody (1:25,000, Sigma-
Aldrich) and with Peroxidase-conjugated AffiniPure donkey anti-rabbit (H+L) secondary
antibody (1:10,000, Jackson ImmunoResearch Laboratories).
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RESULTS
TBX5 and TBX20 are required for heart morphogenesis 
To analyze the requirement for Tbx5 and Tbx20 in cardiogenesis, antisense morpholinos were
designed against the 5’ UTRs and translational start sites of the respective cDNAs (Fig. 2.1).
Due to the lack of antibodies against endogenous TBX5 or TBX20, we tested the efficiency
and specificity of morpholino translation inhibition using V5 epitope-tagged versions of
TBX5 and TBX20 both in vitro and in vivo. To this end, transcription/translation reactions
were incubated with each cDNA construct alone and together with increasing concentrations
of morpholinos (Fig. 2.1). TBX20MO was included as control for TBX5MO and vice versa,
and a ControlMO used for both. Results from these assays show that TBX5MO blocks
translation of TBX5-V5, while TBX20MO and ControlMO do not. Similarly, TBX20MO
blocks translation of TBX20-V5 in vitro (Fig.1B, C).
To determine if TBX5MO and TBX20MO block translation in vivo, we injected
Tbx5-V5 or Tbx20-V5 mRNA alone or in the presence of morpholinos into one-cell stage
embryos. Animal caps were cut at stage 8 and allowed to develop to stage 10, at which point
Western blot analyses were performed. Results from these studies demonstrate that in animal
caps, TBX5MO blocks TBX5-V5 translation, while TBX20MO blocks TBX20-V5
translation (Fig. 2.1D, E). We have further shown via sequence alignments that Tbx5 does
not contain binding sites for the Tbx20 morpholinos and vice versa (Fig. 2.S1; supplementary
data). We did note that the introduction of TBX20MO results in a slight decrease in TBX5 in
vivo, and vice versa (see Discussion).
To determine the requirement of TBX5 and TBX20 in heart development, we injected
TBX5MO, TBX20MO, or ControlMO into one-cell stage embryos. No significant
differences are seen between TBX5 morphants, TBX20 morphants, control morphants, or
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uninjected siblings throughout gastrulation and neurulation stages. However, a slight delay in
developmental stage is evident in TBX5 and TBX20 morphants relative to control morphants
and uninjected embryos by neurulation stage, (~st. 16). By cardiac looping stages, (~st. 38)
(Kolker et al., 2000; Mohun and Leong, 1999; Mohun, 2000; Newman and Krieg, 1999) a
reduction in cardiac mass is evident in the morphants, and by stage 40 both morphants
display grossly abnormal heart morphology (Fig. 2.2A, C, E). At this stage, 82% of TBX5
morphants and 100% of TBX20 morphants display prominent cardiac defects, as scored by
the presence of an unlooped heart tube, a reduction in cardiac mass and the presence of a
pericardial edema (Fig. 2.2G). After terminal cardiomyocyte differentiation has begun (~st.
45) (Kolker et al., 2000; Mohun and Leong, 1999; Mohun, 2000; Newman and Krieg, 1999)
TBX5 and TBX20 morphants display dramatically smaller hearts and in many embryos
cardiac tissue is barely detectable (Fig. 2.2B, C, E, F). However, the remaining cardiac tissue
still retains some degree of contractility, but confined to a small patch of contractile tissue in
the dorsal-most aspect of the cardiac cavity. Embryos derived from injection of Tbx20
morpholinos directed against the antisense transcript, Tbx5 morpholinos containing
mismatches, MOs directed against zebrafish Tbx5 and Gene Tools, LLC’s MO control, gave
no observable phenotype at any concentration (data not shown). These observations, and the
findings that the TBX5 and TBX20 protein levels can be reduced or eliminated both in vitro
and in vivo, suggest that the phenotypes we observe are specific for knocking down TBX5
and TBX20.
To further define the requirements for Tbx5 and Tbx20 during cardiogenesis, we
carried out a detailed analysis of TBX5MO and TBX20MO derived hearts relative to those
from ControlMO injections. For these analyses, staged-matched TBX5MO, TBX20MO, and
ControlMO embryos were collected at stage 37, serial sectioned and stained for the terminal
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differentiation markers Tropomyosin and Cardiac Actin, and counterstained with DAPI (Fig.
2.3). Results from this analysis clearly demonstrate that TBX5MO and TBX20MO derived
hearts fail to undergo cardiac looping and chamber formation. In addition, quantification of
cardiac cell number shows that both TBX5MO and TBX20MO hearts have a significant
reduction in cell number compared to controls, and TBX20MO-derived hearts have a
significantly fewer cardiomyocytes than those from TBX5MO (Fig. 2.3J).
In addition to these defects we note some unique features to both the TBX5MO and
TBX20MO derived hearts, most notably TBX5MO hearts remain as an open cardiac trough
(Mohun et al., 2000) throughout development and fail to form a cardiac tube (Fig. 2.3A-F).
In contrast, TBX20MO derived embryos form a cardiac tube; however, the lumen often
collapses and the hearts concomitantly show a dramatic decrease in the presence of cardiac
actin (Fig. 2.3A-C, G-I). Together this data demonstrates a requirement for both Tbx5 and
Tbx20 in normal heart morphogenesis, and implies that TBX5 cannot compensate for the loss
of TBX20, nor can TBX20 compensate for the loss of TBX5 and suggests that Tbx5 and
Tbx20 play non-redundant roles during normal heart development.
Analysis of hearts derived from TBX5MO and TBX20MO embryos shows a
significant decrease in cardiac cell number. To determine if this is due to alterations in
cardiac cell commitment, we performed whole mount in situ hybridization with the early
heart marker, Nkx2.5 (Fig. 2.4). This analysis was carried out on embryos derived from
TBX5MO, TBX20MO and ControlMO embryos over the period of cardiac cell commitment
and migration and differentiation (stages 16-36). We could detect no obvious difference in
the number or spatial distribution of Nkx2.5-expressing cells prior to stage 24 (Fig. 2.4).
Consistent with our initial analysis, after stage 24 the hearts from TBX5MO and TBX20MO
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embryos are morphologically abnormal and smaller in size, and therefore show a reduced
domain of Nkx2.5 expression.
The above results demonstrate that Tbx5 and Tbx20 are required for normal heart
morphogenesis, but not for specification and migration of the cardiac precursors. To extend
these findings, in situ hybridizations were performed on stage 36 morphants and controls
using the late heart markers atrial natriuretic factor (XANF)(Small and Krieg, 2000) and
cardiac troponin I (XTnIc) (Logan and Mohun, 1993). As shown in Fig. 5, the terminally
differentiated cardiomyocyte marker XTnIc displays properly localized expression in the
cardiac tissue of morphant embryos and appears to be expressed to the same degree, although
due to the reduced cardiac mass it is expressed in fewer cells (Fig. 2.5D-F). XANF is a
putative target of Tbx5, and its expression is reduced in the absence of Tbx5 (Bruneau et al.,
2001). In agreement with these findings, we show that Xenopus TBX5 activates transcription
of a rat Nppa/ANF reporter plasmid (Fig. 2.6) and consistent with TBX5MO blocking TBX5,
XANF expression is either greatly reduced or absent in TBX5 morphants, however, XANF is
still detected in TBX20 morphants (Fig. 2.5A-C). These results indicate that terminal
differentiation still occurs in both TBX5 and TBX20 morphant embryos and implies that
XANF is an evolutionarily conserved target of TBX5.
Tbx5 and Tbx20 are not dependent on each other’s expression 
Since Tbx5 and Tbx20 are co-expressed within the heart and have similar requirements in
heart development, we next asked whether Tbx5 and Tbx20 function linearly within the same
molecular pathway. To address this question, we analyzed the expression of Tbx20 in
TBX5MO-injected embryos and Tbx5 expression in TBX20MO-injected embryos. We could
detect no differences in the expression of either gene in morpholino-injected embryos (Fig.
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2.7); both genes remain expressed in the forming heart tissue, despite the reduction of cardiac
tissue mass in morpholino-injected embryos. Based on these results we conclude TBX5 is not
essential for Tbx20 expression, nor is Tbx20 dependent on TBX5.
TBX5 affects TBX20 transcriptional activity  
Our results strongly suggest that Tbx5 and Tbx20 do not function linearly within the same 
pathway yet have a similar requirement in heart development. We therefore carried out a 
series of experiments to test if TBX5 and TBX20 have either competing or complimentary 
functions at the molecular level. We first tested the cellular localization of TBX5 and 
TBX20. For these studies V5 epitope-tagged versions of the full-length cDNAs were 
transfected into NIH/3T3 cells. Immunohistochemistry on the transfected cells show that 
similar to TBX5 (Collavoli et al., 2003; Fan et al., 2003; Zaragoza et al., 2004), TBX20 is 
localized exclusively to the nucleus. (Fig. 2.6C-H)  
 We next tested if TBX5 and TBX20 can function to regulate the levels of
transcription of the TBX5 target gene Nppa/ANF. To test for DNA specific binding and
transcriptional activities, we transfected in full-length versions of Tbx5 and Tbx20, either
alone or in combination, with the putative Tbx5 target Nppa/ANF reporter construct into
293T cells. Consistent with studies using the mouse Tbx5 orthologue (Hiroi et al., 2001),
TBX5 can weakly activate the rat Nppa/ANF reporter. In contrast, Tbx20 alone can activate
the Nppa/ANF in a dose dependent fashion. However, in the presence of TBX5, TBX20 can
have the converse effect on the Nppa/ANF reporter. In the presence of TBX5, at high and low
doses of TBX20 there is increased activation of the reporter construct, while at moderate
doses there is a repressive effect (Fig. 2.6I). Thus, the presence of TBX5 appears to alter
TBX20 transcriptional activity.
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TBX5 and TBX20 physically interact with one another 
Given the similarity in phenotypes of TBX5 and TBX20 morphant embryos, and the
observation that Tbx5 and Tbx20 are not dependent on one another’s expression, we next
assessed whether TBX5 and TBX20 can physically interact. TBX5 fused to Glutathione-S-
Transferase (GST) was incubated with HA-tagged TBX20 or NKX2-5. Pulldown
experiments were then performed to assess whether TBX20 can bind to TBX5. NKX2-5 has
been shown to interact with TBX5 and thus serves as a positive control (Hiroi et al., 2001).
As shown in Fig. 2.8A, bacterially translated GST-TBX5 is able to bind HA-TBX20 and
HA-NKX2-5 produced from 293T cells, in contrast to GST alone, which does not bind either
protein. These results reveal that TBX5 and TBX20 can interact in vitro. This is the first
report of physical interaction between T-box proteins.
Having demonstrated that TBX5 and TBX20 interact, we next mapped the interaction
domains of TBX5 and TBX20. To this end, we constructed a deletion series of both GST-
tagged TBX5 and HA-tagged TBX20. As shown in Fig. 2.8B, GST-TBX5 proteins lacking
the C-terminus still bind HA-TBX20, however when the small N-terminus and T-box domain
are removed from GST-TBX5, HA-TBX20 fails to bind. Thus, the domain responsible for
TBX20 binding lies within the N-terminus and T-domain of TBX5. Similarly, a C-terminal
deletion of HA-TBX20 still binds to GST-TBX5, in contrast to deletions of the HA-TBX20
N-terminus and T-domain (Fig. 2.8C). As seen in the •N/C lane in Fig. 2.8C, the HA-TBX20
deletion containing only the T-box domain did not bind GST-TBX5. However, we were
unable to obtain comparable amounts of the HA-T20-•N/C protein, as seen in the input lane.
This could be due to mRNA or protein instability. In an attempt to circumvent this problem,
the amount of HA-T20-•N/C protein incubated with GST-TBX5 was increased 2-fold as
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compared to the rest of the experiments. These results indicate that the N-terminus and
possibly the T-domain of TBX20 are required for its interaction with TBX5, although we
cannot rule out the possibility that the amount of HA-T20-•N/C protein was insufficient to
identify a requirement for the T-domain. In summary, our results reveal that the domains
responsible for the interaction between TBX20 and TBX5 map to within the N-terminal and
T-box domains in both proteins.
Tbx5 and Tbx20 cooperate to regulate heart morphogenesis 
Given that TBX5 and TBX20 physically interact with one another, we hypothesized that
Tbx5 and Tbx20 may function cooperatively to control cardiogenesis. To test this hypothesis,
we coinjected concentrations of TBX5MO and TBX20MO below the threshold at which
cardiac phenotypes are efficiently induced when injected individually. At a concentration of
40 ng per embryo for Tbx5 morpholinos and 80 ng per embryo for Tbx20 morpholinos,
injections yield consistent heart phenotypes in 82% of TBX5MO-injected embryos and in
100% of TBX20MO-injected embryos (Fig. 2.2). We refer to this dose as the “optimal” dose,
because it is the dose at which we observe the efficient and penetrant cardiac phenotypes. At
half doses, 20 ng per embryo for TBX5MO and 40 ng per embryo for TBX20MO, each
morpholino yields significantly fewer and weaker heart phenotypes compared to the full dose
(Fig. 2.9M, data not shown). We refer to this concentration as the “suboptimal” dose for
inducing cardiac defects. The terms “optimal” and “suboptimal” are only used to refer to the
concentrations that yield fully penetrant or partially penetrant cardiac phenotypes,
respectively.
To address the question of whether Tbx5 and Tbx20 cooperate in cardiogenesis, we
injected TBX5MO and TBX20MO individually at suboptimal doses in combination with
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ControlMO to keep total morpholino concentrations equal in all injections. TBX5MO was
then coinjected with TBX20MO, each at the suboptimal dose. ControlMO injected at 80
ng/embryo served as control. As shown in Fig. 2.9, only 4% of embryos injected with
suboptimal TBX5MO/ControlMO displayed a pericardial edema, unlooped heart tubes, and a
reduction in cardiac mass. Suboptimal TBX20MO/ControlMO yields only 13% cardiac
defects. In suboptimal injections, the majority of embryos appeared normal, while the few
cardiac phenotypes produced were much less severe than at optimal doses (e.g. barely
detectable reduction in cardiac mass, slight perturbation of looping and little or no pericardial
edema). When coinjected at suboptimal doses, 74% of TBX5MO/TBX20MO coinjected
embryos display dramatic cardiac defects compared to 0% of ControlMO-injected embryos
(Fig. 2.9D, H, L). The observation that the percentage of heart defects in double morphants is
more than additive suggests that Tbx5 and Tbx20 synergistically act to control heart
morphogenesis.
If Tbx5 and Tbx20 cooperate to regulate cardiogenesis, one might expect a more
severe alteration in cardiac morphology and marker expression when the levels of both
proteins are reduced. To address this question we performed in situ hybridizations on stage
36 embryos from the above double injection experiment using Nkx2-5, XANF, and XTnIc
probes. As shown in Fig. 2.9, all three markers are expressed normally in embryos injected
with suboptimal doses of TBX5MO and TBX20MO as compared to ControlMO. However,
heart marker expression in the double morphant embryos is markedly reduced, particularly
XANF. Both Nkx2-5 and XTnIc are still detectable in the heart region, albeit in fewer cells.
Thus, the synergistic cooperation of TBX5 and TBX20 are required for proper heart
development.
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DISCUSSION
Members of the T-box family of proteins play a fundamental role in patterning the
developing vertebrate heart, however, the precise cellular requirements for any one family
member remains largely unknown. In this study, we demonstrate that TBX5 and TBX20 are
both required for early cardiac morphogenesis. Moreover, we show that TBX5 and TBX20
function in the same pathway implying a synergistic role for these two proteins during early
heart development. Consistent with this proposal, we show that TBX5 and TBX20 can
physically and functionally interact, therefore providing the first evidence for direct
interaction between members of the T-box gene family.
Functions of Tbx5 and Tbx20 in Cardiac Morphogenesis 
Our studies show that Tbx5 and Tbx20 are required for similar cellular processes in the
developing heart. This data demonstrates a non-redundant function for TBX5 and TBX20
during cardiac morphogenesis; neither protein can compensate for the other in heart
morphogenesis. The lack of redundancy at the molecular level is corroborated by the
observation that the putative TBX5 target gene XANF either is not expressed or is expressed
very weakly in TBX5 morphant embryos, while being expressed at the proper time, place and
levels in TBX20 morphant embryos. Together this data suggests that TBX5 and TBX20 act
in a non-redundant fashion to control morphogenetic movements of early heart tissue.
The cardiac defects in response to a reduction of either TBX5 or TBX20 appear to
represent a block in an early morphological step in heart formation. Since the spatial
distribution of Nkx2-5 is unaltered throughout early development in TBX5MO, TBX20MO
and ControlMO injected embryos, and since Nkx2.5, Tbx5, and Tbx20 continue to be
expressed until the later stages of heart development, and TBX5 and TBX20 morphants
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express markers of terminal muscle differentiation, neither Tbx5 nor Tbx20 appear to be
required for commitment, migration or terminal differentiation of cardiac tissue. Thus, both
Tbx5 and Tbx20 appear to be required to direct the coordinated events that occur during the
early steps of heart morphogenesis.
Consistent with this hypothesis, both TBX5 and TBX20 morphant derived hearts are
greatly extended along the anterior-posterior axis, and the heart tube fails to correctly loop
and undergo chamber formation. As a result, embryos display pericardial edemas, have
impaired blood flow (Fig. 2.S2; supplementary data), an irregular heartbeat (data not shown)
and ultimately die. Thus, the alteration in heart morphology appears to be the primary
outcome of perturbing TBX5 or TBX20 function.
Past attempts to interfere with Tbx5 function in X. laevis were carried out by the
misexpression of a putative interfering form of Tbx5 that leads to either the absence or severe
malformations of the heart (Horb and Thomsen, 1999). In instances in which the heart does
form, there is a reduction or block in myocardial tissue formation and a failure of the heart to
undergo looping. Our results with Tbx5-specific morpholinos show a less severe heart
phenotype than those reported with the dominant interfering Tbx5 but bear a close
resemblance to those reported for the zebrafish Tbx5 mutant, heartstrings (Garrity et al.,
2002). This may be due to the dominant-interfering form of Tbx5 used in the X. laevis studies
interfering with the function of both Tbx5 and Tbx20 or possibly other T-box family
members expressed in the developing heart, e.g. Tbx1 and Tbx2 (Chapman et al., 1996), as
has been shown for other Engrailed fusions (Horb and Thomsen, 1997). However, in the
absence of a TBX5 specific antibody, we cannot formally rule out the possibility that some
residual TBX5 protein is present in morphant embryos leading to a less severe phenotype in
our studies.
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Tbx5 and Tbx20 are not dependent on one another’s function 
The phenotypes of TBX5 and TBX20 morphant embryos do not appear to act in a linear
pathway since the spatial and temporal expression of Tbx5 appears unaltered in TBX20
morphants, and vice versa. These findings are in agreement with studies showing normal
expression of Tbx20 in Tbx5 mutant mice (Stennard et al., 2003) but in apparent conflict with
a second study reporting the downregulation of Tbx5 in zebrafish embryos injected with a
Tbx20 morpholino (Szeto et al., 2002). Although the zebrafish and X. laevis orthologues of
Tbx20 share a very high degree of identity at the protein level (86%), the differences between
the two orthologues may reflect a species difference as, for example, has been reported for
the endodermal-inducing activities of the T-box-containing gene Brachyury (Marcellini et al.,
2003). Although no alterations in Tbx5 or Tbx20 RNA levels were observed in morphant
embryos, we did observe a downregulation of TBX5 protein in response to Tbx20
morpholinos in vivo, and vice versa, but not in vitro (Fig. 2.1), raising the interesting
possibility that cross-regulation may be occurring between TBX5 and TBX20 at the level of
translation. Since similar studies have not been conducted in zebrafish, it is not possible at
this time to know the mechanisms of cross-regulation or if this is a conserved response to
interfering with TBX5 or TBX20.
TBX5 and TBX20 Heterodimerization 
Although Tbx5 and Tbx20 are coexpressed and both function in early heart development, the
genes appear to be regulated through separate pathways. For example, Tbx20 but not Tbx5
can be induced in response to BMP2 signaling (Plageman and Yutzey, 2004). Taken together
with our results demonstrating a physical interaction between TBX5 and TBX20, these data
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would suggest that TBX5 and TBX20 function in parallel pathways that converge upon
TBX5:TBX20 heterodimerization. This model is also supported by our results showing a
functional interaction between TBX5 and TBX20: embryos derived from injections of
suboptimal doses of Tbx5 and Tbx20 morpholinos have only minor effects on heart
development in a small proportion of the embryos. However, when injected in combination
74% of all embryos examined displayed grossly abnormal heart formation.
What are the possible cellular functions of TBX5 and TBX20 in heart development?
Past studies on T-box genes have shown a direct link between members of the T-box gene
family and cell adhesion. For example, embryos homozygous for mutations in Brachyury, the
founding member of the T-box gene family, show an inability of the mesoderm to properly
migrate along the extracellular matrix leading to an inability of the mesodermal germ layer to
complete the morphogenetic movements normally associated with gastrulation (reviewed in
Showell et al., 2004). We propose an analogous model for TBX5 and TBX20 function in
regulating cell polarity or adhesion events associated with heart morphogenesis. We propose
that TBX5 and TBX20 function to control polarity or adhesive properties of cardiac tissue
once the two heart fields merge along the anterior midline, and that target specificity is
regulated through TBX5 and TBX20 protein-protein interactions. In agreement with this
proposal, we have recently shown that alterations in cardiac cell numbers, survival and
proliferation in TBX5MO derived embryos are a consequence of disrupting TBX5 function
(S. Goetz and FLC, in preparation). This observation, taken together with our findings that
cardiac gene expression patterns are not disrupted in TBX5MO or TBX20MOs derived
embryos, suggests that the primary role for TBX5 and TBX20 is to control cardiac cell
polarity or adhesion.
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It is worth noting that neither TBX5 nor TBX20 have strong transcriptional activation
or repression activity by themselves (Bruneau et al., 2001; Hiroi et al., 2001; Plageman and
Yutzey, 2004; Stennard et al., 2003). Thus, transcriptional activity appears to be governed by
protein-protein interactions. Past studies have identified several other interacting partners for
both TBX5 and TBX20. For example, both TBX5 and TBX20 have been shown to interact
with the homeobox-containing transcription factor NKX2-5 (Bruneau et al., 2001; Hiroi et
al., 2001; Stennard et al., 2003), consistent with clinical studies showing that HOS patients
and humans heterozygous for NKX2-5 display many of the same cardiac defects (Elliott et
al., 2003; Goldmuntz et al., 2001; Prall et al., 2002).
How might TBX5:TBX20 heterodimerization affect target choice? It may be that the
role of TBX5:TBX20 dimerization is to sequester TBX5 and thereby block its interaction
with other proteins such as NKX2.5 thereby indirectly inhibiting the induction of cardiac
specific genes such as XANF. However, several lines of evidence argue against such a
proposal. For example, at low and high concentrations TBX20 can increase transcription of
the Nppa/ANF reporter in the presence of TBX5, while showing a repressive activity at
intermediate concentrations, suggesting that in certain contexts TBX20 can cooperate with
TBX5 to activate transcription, while antagonizing TBX5 activity in others. An alternative
possibility is that TBX20 target choice and ability to function as a transcriptional activator or
repressor is governed by its choice of interacting partners. Consistent with this hypothesis,
Stennard et al (2003) have shown that NKX2.5, GATA4, and GATA5 interact with TBX20,
and the interactions occur through the same domain of TBX20 that we have shown interacts
with TBX5, at least in the cases of NKX2.5 and GATA4. Furthermore, the authors
demonstrated that TBX20 can repress synergistic activation of a connexin 40 reporter by
NKX2.5 and GATA4, while synergistically activating the same reporter with NKX2.5 and
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GATA5. Thus, TBX20 may be able to function both as a transcriptional activator or
repressor, and this decision is based on its choice of protein partners. In addition, TBX5 and
TBX20 have been shown to display different binding affinities for different T-box binding
sites (Stennard et al., 2003). For example, TBX20 unlike TBX5 can bind to the Brachyury
target site while TBX5 has a higher affinity than TBX20 for the T-box binding site in the
Nppa/ANF promoter. Thus, downstream target selection may be dictated by
homodimerization verses heterodimerization. This is supported by the recent findings that
several genes involved in heart development are found to contain multiple T-box binding
sites (R. Schwartz personnel communication, FLC unpublished findings). Our model would
suggest that TBX5 and TBX20 target selection and transcriptional activity is based on
partner choice in a specific tissue at a specific time. However, it still remains to be
established which protein interactions take place in the developing heart and in turn, what
governs the choice of partners for TBX5 or TBX20. These are presently areas under active
investigation.
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Figure 2.1. Tbx5 and Tbx20 morpholinos block translation of their respective target
proteins.
(A) TBX5MO and TBX20MO positions relative to Tbx5 and Tbx20 cDNA. (B) Inhibition of
TBX5-V5 translation in vitro by TBX5MO. TBX20MO and ControlMO serve as controls.
Each reaction contains 1ug of Tbx5-V5 circular plasmid along with the indicated amounts of
MO. (C) Inhibition of TBX20-V5 translation in vitro by TBX20MO. TBX5MO and
ControlMO serve as controls. Each reaction contains 1ug of Tbx20-V5 circular plasmid along
with the indicated amounts of MO. (D) Inhibition of TBX5-V5 translation by TBX5MO in
animal caps. TBX20MO and ControlMO serve as controls. Probed with anti-V5 and re-
probed with anti-PTP1D/SHP2 as a loading control. Embryos injected with 2 ng mRNA and
the indicated amounts of MO. (E) Inhibition of TBX20-V5 translation by TBX20MO in
animal caps. TBX20MO and ControlMO serve as controls. Probed with anti-V5 and re-
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probed with anti-PTP1D/SHP2 as a loading control. Embryos injected with 2 ng mRNA and
the indicated amounts of MO.
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Figure 2.2. Tbx5 and Tbx20 are required for proper cardiogenesis.
(A-F) Morpholino-injected tadpoles at the indicated stages. Control morphant embryos (A,
B), TBX5 morphant embryos (C, D), TBX20 morphant embryos (E, F). Arrows indicate the
heart region, arrowheads indicate the eye. Note the reduction in eye tissue in response to
TBX5MO but not TBX20MO. (G) Chart displaying the percentage of morphants surviving
and displaying cardiac abnormalities as scored by the presence of an unlooped heart tube, a
reduction in cardiac mass and the presence of a pericardial edema.
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Figure 2.3. TBX5 and TBX20 morphants fail to undergo looping and chamber formation and
display reduced cardiac cell numbers.
Cryosections of TBX5 and TBX20 morphant hearts. (A-C) ControlMO, (D-F) TBX5MO,
and (G-I) TBX20MO. Sections stained for Cardiac Actin (green), Tropomyosin (red) and
DAPI (blue). (J) Mean number of cells per heart counted.
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Figure 2.4. Cardiac specification is unaltered in TBX5 and TBX20 morphants.
Wholemount in situ with Nkx2.5 on stage matched (A,D, G, J) ControlMO, (B,E,H,K)
TBX5MO, or (C, F, I, L) TBX20MO derived embryos.
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Figure 2.5. TBX5 and TBX20 morphants display dramatic morphological defects.
Whole-mount in situ hybridizations of cleared stage 36 embryos. (A-C) ANF whole mount in
situ hybridization. (D-F) XTnIc whole mount in situ hybridization. (A, D) ControlMO. (B,
E), TBX5MO, (C, F) TBX20MO.
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Figure 2.6. Tbx5 and Tbx20 are localized to the nucleus and can activate transcription on
the Nppa/ANF promoter.
(A) Schematic depicting the amino acid positions of the T-box domains of Tbx5 and Tbx20.
(B) Schematic of Rat Nppa/ANF-luciferase reporter construct showing T-box binding site
consensus sequences and their relative position within the promoter relative to translation
start site. (C,F) Transfected cells were stained with anti-V5 (Cy2, green) for TBX5-V5 and
TBX20-V5 and (D,G) anti-phosphotyrosine (Cy3, red) to visualize cytoplasmic
compartment. (E,H) Overlay image of Cy2 and Cy3 staining. (I) Rat ANF-luciferase co-
transfected with a constant amount of Tbx5 (50 ng) and increasing amounts of Tbx20 (25, 50,
100 and 500 ng) in 293T cells and level of transcriptional activation expressed as Relative
Luciferase Units based on average of three independent experiments performed in triplicate.
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Figure 2.7. Tbx5 and Tbx20 are not required for each other’s expression.
Embryos injected at the one-cell stage with ControlMO, TBX5MO, or TBX20MO. (A, C)
Whole-mount in situ hybridization showing Tbx5 expression. (B, D) Whole-mount in situ
hybridization showing Tbx20 expression.
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Figure 2.8. TBX5 and TBX20 physically interact.
Cell lysates containing GST- and/or HA-tagged proteins were incubated on GST and eluted,
and separated by SDS-PAGE. GST proteins were detected using anti-GST antibodies and
HA-tagged proteins were detected with anti-HA antibodies. (A) Association of TBX5 with
TBX20 is shown by pulldown of HA-TBX20 with GST-TBX5. HA-NKX2-5 serves as
positive control. 15% of output and 7.5% of input was probed. (B, C) Pulldown of full-length
HA-TBX20 with a GST-tagged TBX5 deletion series reveals an interaction domain in the N-
terminus and T-box region of TBX5. Each reaction was probed with anti-HA antibodies.
7.5% of input and 15% of output was probed. (C, D) Pulldown of HA-TBX20 deletion series
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with full-length GST-TBX5 reveals an interaction domain within the N-terminus and T-box
of TBX20. Each reaction was probed with anti-HA antibodies. 7.5% of input and 15% of
output was probed, except in the case of •N/C in which the amount of protein probed was
only 4% due to the increase in total amount of •N/C protein used in pulldown (see text).
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Figure 2.9. Tbx5 and Tbx20 synergistically act to regulate cardiac gene expression.
(A-L) Embryos injected with the indicated morpholinos at the one-cell stage. (A-D) Nkx2-5 
whole mount in situ hybridization. (E-H) XANF whole mount in situ hybridization. (I-L)
XTnIc whole mount in situ hybridization. (A, E, I) ControlMO, (B, F, J) TBX5MO injected
at suboptimal dose, (C, G, K) TBX20MO injected at suboptimal dose, (D, H, L) TBX5MO
and TBX20MO injected in combination at suboptimal doses. All embryo were cleared to
reveal heart expression. (M) Statistics for embryos injected with suboptimal doses of
TBX5MO and TBX20MO in combination with each other or with ControlMO. Hearts were
judged as having defects if they displayed a pericardial edema, an unlooped heart tube, or
reduction in cardiac mass.
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Figure 2.S1. Sequence alignments suggest that Tbx5 and Tbx20 morpholinos cannot cross
react.
(A) Alignments of Tbx5 morpholinos (complementary sequence) with Tbx5 and Tbx20
mRNA sequence. (B) Alignments of Tbx20 morpholinos (complementary sequence) with
Tbx5 and Tbx20 mRNA sequence.
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Figure 2.S2. Tbx5 and Tbx20 morpholinos block the formation of a functional heart as
assayed by benzidine staining of erythrocytes in stage 42 tadpoles.
(A) Uninjected control, (B) TBX5MO injected at optimal dose, (C) TBX20MO injected at
optimal dose, (D) TBX5MO and TBX20MO injected together at suboptimal doses. Note:
Blood staining in the heart region (h) of control embryos but not morphant embryos.
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CHAPTER 3 
 
A 3D Modeling Program to Rapidly Assess Cardiac 
Morphological Abnormalities in Vertebrate Embryos 
 
PREFACE TO CHAPTER 3
Chapter 3 describes a 3-D modeling program developed in collaboration with the laboratory 
of Dr. Stephen Aylward.  The purpose of this modeling program is to rapidly re-assemble 
serial sections through the developing heart into a 3-D reconstruction in order to assess the 
overall structure of the heart in greater detail than is possible through examination of 
wholemount tissue.  We use embryos depleted of TBX-5 as a case study for the utility of this 
program in examining morphological abnormalities in the heart.  This project was carried out 
in collaboration with Yvette Langdon, Tamaryn Kelley, Ashley Hayes, Jennifer Duddy, 
Remi Charrier, Cedric Caron, and Stephen Aylward.  For this work, I performed serial 
sectioning, immunostaining and reconstruction of hearts from control, and TBX5 depleted 
embryos. 
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SUMMARY
Characterizing the cellular and molecular basis of heart development largely depends 
on the ability to describe normal heart development, as well as cardiac phenotypes 
arising from the disruption of specific molecular pathways.  To build upon existing 
techniques for the examination of cardiac morphology during development, we have 
devised a 3-D modeling program known as HistologicalImageReconstruction.  This 
program provides an inexpensive and rapid method for characterizing the morphology 
of the heart or other tissue of interest at a high level of detail.  Here we provide a 
demonstration of the utility of HistologicalImageReconstruction to analyze both normal 
cardiac development, and the cardiac phenotype resulting from depletion of the 
transcription factor TBX5 during Xenopus laevis development. 
 
INTRODUCTION
Congenital heart defects are among the most common forms of birth defects in humans, 
comprising approximately 1% of all live births (Hoffman, 1995a, 1995b).  In recent years, 
numerous studies have elucidated many of the basic processes of heart development, 
employing both embryological and molecular approaches (Bruneau, 2002; Kolker et al.,
2000; Mohun, 2000; Olson and Srivastava, 1996) .  However, in spite of this, our 
understanding of the molecular mechanisms underlying normal heart development, as well as 
the mechanisms of human disease states remains incomplete.   
 Understanding the molecular mechanisms of heart development relies upon the 
ability to accurately describe both normal heart development and abnormalities resulting 
from the disruption of certain gene products or molecular pathways.  Existing tools for 
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visualizing cardiac phenotypes consist primarily of whole-mount immunostaining, and 
immunostaining of histological sections.  Whole-mount immunostaining allows for the 
visualization of overall cardiac morphology, but is somewhat limited in ability to detect more 
subtle defects.  In contrast, histological sections provide a greater degree of detail and more 
easily allow for quantitative analysis of a cardiac phenotype, such as determination of cell 
number.  However, visualization of the overall morphology of the heart is often not possible 
using this technique. 
To address the limitations of these methods, we have devised an inexpensive, high-
throughput 3-dimensional modeling program, known as HistologicalImageReconstruction, 
that combines the detail of histological sections with the ability to easily observe the overall 
morphology of the heart.  Briefly, the modeling program consists of four steps: segmentation, 
stitching, stacking and the three dimensional reconstruction.   Utilizing sections through the 
Xenopus heart that have been stained with a cardiac muscle-specific antibody such as myosin 
heavy chain a 3-dimensional model of the heart can be rendered.  The heart in each serial 
section is selected during segmentation and the images are stacked together based on 
reference points provided by the previous image.  The stacked images are then converted to a 
3D model that can be visualized using the VisualizeHistologyImage program which is a 
companion program to HistologicalImageReconstruction.   
Xenopus is an especially valuable tool for the study of cardiovascular development 
because, unlike mammalian embryos, amphibian embryos can survive to late developmental 
stages without functional circulation.  Xenopus embryos are highly amenable to 
embryological manipulations and, with the advent of antisense morpholino technology, it has 
been possible to generate highly specific loss-of-function phenotypes for many genes of 
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interest.  Amphibian embryos also possess pulmonary circulation making the physiology of 
their circulatory system more closely related to that of the mammals than is the zebrafish.   
While other modeling programs to examine heart development in Xenopus have been 
described (Mohun, 2000), the program we have developed offers several advantages and thus 
complements existing modeling programs.  First, in HistologicalImageReconstruction, the 
3D model can be reconstructed solely from corresponding points on adjacent sections 
through the heart without requiring the use of reference points outside the heart upon which 
to align the 3D model.  As a result, HistologicalImageReconstruction requires the use of less 
tissue and allows for a rapid reconstruction of 3D images.  In addition, 
HistologicalImageReconstruction utilizes the expression of cardiac muscle proteins to define 
the cardiac tissue to be imaged.  In this way, we are able to distinguish cardiac tissue from 
surrounding mesoderm more easily at earlier developmental stages or in regions of the heart 
that are not morphologically well defined.  Thirdly, this program can reconstruct hearts from 
florescent immunostaining, or from in situ hybridization without necessitating expensive 
software.  Thus, this method also allows us to catalog and compare the expression patterns of 
various heart proteins throughout development. 
 
RESULTS AND DISCUSSION 
To demonstrate the utility of the modeling program as a tool for analyzing normal heart 
development, we initially reconstructed 3D models of Xenopus hearts at three developmental 
stages, determined according to Nieuwkoop and Faber (Nieuwkoop and Faber, 1967); stage 
29, which corresponds to the folding of the cardiac field into the bilaminar heart tube; stage 
33, which corresponds to the onset of cardiac looping; and stage 37, corresponding to early 
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cardiac remodeling and chamber formation.  At each of these stages hearts were serial 
section and immunostained with an antibody against cardiac myosin heavy chain (MHC) or 
tropomyosin.  Representative sections from the anterior, middle, and posterior regions of the 
heart for each stage are shown in Fig. 3.1.  The series of sections were then used to 
reconstruct a 3D model of the heart for each stage and visualized by 
VisualizeHistologyImage (Fig. 3.2).  These models reveal the overall morphology as detected 
by staining with cardiac specific antibodies of the heart at each stage as well as cataloging the 
expression of genes/ proteins at each of these developmental stages.  Through the 
visualization program, the rendered surface of the heart can be made transparent and each 
individual section of the heart viewed providing internal details of the heart relative to overall 
heart morphology.      
The model based on MHC expression of unmanipulated embryos at stage 29 shows 
that the bilateral Xenopus heart primordia have joined across the ventral midline to form a 
single heart field.  The heart field has begun to round up to form a trough that is open at the 
dorsal-most aspect (Fig. 3.2a-c).  At this stage the heart and MHC expression are in a linear 
configuration, with the presumptive inflow and outflow of the heart aligned along the 
anterior-posterior axis (Fig. 3.2b-arrows).   
By stage 33, the heart tube is fully closed for much of its length (Fig. 2d-f), with the 
exception of the anterior-most portion of the heart, near the future outflow tract, where it 
remains open at the dorsal aspect (Fig. 3.2e-arrowhead).  By this stage, the heart has begun 
the morphogenetic process of rightward looping, as seen by the visible offsetting of the 
inflow to the right of the outflow (Fig. 3.2e-arrows).  At this stage the MHC expression 
domain has also increased in size due to high levels of cell proliferation within the Xenopus 
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heart (Goetz et al., 2006), and has increased in length along the anterior-posterior axis (Fig. 
3.2- compare f with c).   
Finally, at stage 37, a greater degree of morphological complexity is evident as the 
heart continues to undergo cardiac looping and begins cardiac remodeling (Fig. 3.2g-i).  At 
this stage, the heart elongates along the left-right axis (Fig. 3.2h), and the chamber primordia 
become more distinct (Fig. 3.2g,i-arrow heads).  As was the case at stage 33, the hearts of the 
stage 37 embryos have fully closed with the exception of the anterior-most sections, although 
the dorsal opening in these anterior sections is more narrow than that of the stage 33 embryos 
(Fig. 3.2-compare d with g), suggesting that the anterior portion of the heart at stage 37 is 
continuing to complete dorsal closure to form a fully enclosed tube.  By this point in 
development, our HistologicalImageReconstruction-generated model reveals that the outflow 
tract of the heart is still shifted to the right with respect to the inflow (Fig. 3.2h-arrows).   
To show the utility of the HistologicalImageReconstruction modeling program in 
characterizing morphological abnormalities arising from loss or mis-expression of a 
particular gene product, we analyzed embryos in which we depleted TBX5 by morpholino 
antisense oligos, as a test case (Brown et al., 2005; Goetz et al., 2006).  Mutations to the T-
box transcription factor Tbx5 are associated with the congenital heart disorder Holt-Oram 
syndrome in humans (Basson et al., 1997; Li et al., 1997) and the evolutionarily conserved 
requirement for TBX5 during heart development demonstrated in a number of vertebrate 
species (Bruneau et al., 2001; Garrity et al., 2002; Horb and Thomsen, 1999).  Previously we 
have shown that depleting TBX5 in Xenopus leads to a reduction in heart size and a failure to 
undergo cardiac looping and chamber formation (Brown et al., 2005; Goetz et al., 2006).  
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Our  HistologicalImageReconstruction- generated 3D models of hearts from embryos 
lacking TBX5, shown in Fig. 3, are consistent with these previous finding, while also 
revealing differences in morphology between control and TBX5-depleted embryos that were 
not previously described (Brown et al., 2005; Goetz et al., 2006).    In control hearts at stage 
29, the ventrally-fused heart field has begun to round up dorsally to form the linear heart tube 
(Fig. 3.3a,c).  In TBX5-depleted hearts, tropomyosin positive cells of the cardiac field failed 
to migrate towards the dorsal side of the embryo to initiate heart tube formation (Fig. 3.3b,d).  
In addition, the number of cells expressing tropomyosin is reduced compared to controls.  As 
previously reported, this most likely reflects a delay in the timing of expression of 
tropomyosin in TBX5-depleted embryos (Goetz et al., 2006).   
At stage 33, control and TBX5-depleted embryos contain approximately equal 
numbers of tropomyosin positive cells, however, several morphological abnormalities 
become apparent in the expression of tropomyosin in TBX5-depleted embryos (Fig. 3.3g-l). 
In control embryos, consistent with what we observed for the models based on MHC 
staining, the heart tube is fully closed for much of its length with the exception of the most 
anterior portions of the heart (Fig. 3g,i).  Cardiac tissue has begun the process of cardiac 
looping (note: the inflow tract is noticeably offset to the right from the outflow tract; Fig. 
3.3i- arrows).  In comparison, hearts of the TBX5-depleted embryos at stage 33 still form a 
trough opening dorsally for all but a small, central portion of the heart tube (Fig. 3.3h-blue 
arrow).  The hearts derived from TBX5-depleted embryos have also failed to initiated cardiac 
looping (note: inflow tract is aligned with the outflow along the anterior-posterior axis, rather 
than offset to the right; Fig. 3.3j-arrows).   
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By stage 37, control embryo tropomyosin staining marks the chamber primordia (Fig. 
3.3m,o-arrowheads).  In contrast, the hearts of TBX5- depleted embryos show fewer 
tropomyosin-positive cells (Fig. 3n,p,r).  In addition, the inflow and outflow tracts are 
aligned along the anterior-posterior axis, indicating that the heart has failed to undergo 
cardiac looping (Fig. 3.3p-arrows) (Goetz et al., 2006).  We also observe that the central 
portion of the dorsal aspect of the heart tube remains as an open trough (denoted by the blue 
arrow; Fig. 3.3p).  Interestingly, it appears that blood flow into the heart tube of the TBX5-
depleted embryos may be offset dorsally, as the anterior most portions of the heart tube are 
occluded (Fig. 3.3n-blue arrow).  This observation indicates that the defects seen in the 
TBX5-depleted embryos are not simply due to a delay in heart development, as the 
morphological abnormalities are more severe than those seen in earlier stage control hearts.   
Our HistologicalImageReconstruction-generated 3D models both accurately 
recapitulate antibody expression patterns and hence morphological defects in TBX5-depleted 
cardiac tissue.  These include the failure of the heart to properly form a linear heart tube, 
defects in the relative positioning of the heart, and a general decrease in cardiac mass.  
Although the software has allowed a rapid evaluation of molecular expression patterns and 
cardiac defects in Xenopus, the program can be easily adapted or other tissues, organs, or 
model organisms.  A considerable advantage offered by our 3D modeling is its use of 
immunostaining to label the tissue of interest to be modeled.  Thus, this program offers 
inexpensive, high-throughput 3D imaging to investigators wishing to study alterations in 
tissues that may not be morphologically distinct from the surrounding tissue during the 
developmental window of interest. 
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METHODS 
 
Cryosectioning and Immunostaining of Heart Tissue 
For immunostaining of histological sections, embryos were collected at the indicated stages, 
fixed for 2 hours in 4% paraformaldehyde, and embedded in OCT cryosectioning medium 
(Tissue Tek).  Serial cryostat sections  (14Om) corresponding to the entire heart region were 
collected and rinsed with wash buffer (PBS with 1% Triton and 1% heat inactivated calf 
serum), and incubated at 4 ºC overnight as indicated with mouse anti-tropomyosin 
(Developmental Studies Hybridoma Bank) at 1:50; or  mouse anti-myosin heavy chain  
(Abcam) at 1:1000.  The sections were rinsed with wash buffer and the fluorescent 
conjugated secondary antibody, anti-mouse-Cy3 (Sigma), was applied to the samples, diluted 
in wash buffer at 1:100.  The slides were incubated with secondary antibody for 30 minutes 
at room temperature and rinsed with wash buffer.  Samples were then incubated 30 minutes 
at room temperature with DAPI (Sigma) to stain nuclei.  The samples were imaged on a 
Nikon E800 epiflourescent microscope and images captured using the Metamorph software 
package (Universal Imaging Corporation). 
 
3-D Reconstruction 
3D reconstruction of sectioned cardiac tissue was performed using the software  package 
HistologyImageReconstruction designed by the University of North Carolina’s Computer 
Aided Diagnosis and Display lab.  Digital images of the histological sections were loaded 
into the histology program.  To construct a 3D model positive staining cells of the heart were 
identified by immunostaining with a heart-specific antibody.  All positive staining cells 
within the section were then selected based on relative staining intensity and pixels selected.  
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Tissue not recognized by the heart-specific antibody was thus eliminated from the model.  
Following the selection of heart tissue in each histological section in the series, 
corresponding points in each consecutive section were choosen (n= 4-8) and aligned by the 
HistologicalImageReconstruction software program.  These corresponding points were 
chosen based upon a starter section containing the most morphologically distinct portion of 
the heart.  A minimum of four corresponding points were then chosen in the remaining 
sections of each heart.  The 2D images of the series were then transformed to allow for 
rotation, shifting, and deformation based on the images.  The transformed sections were then 
examined to assess the alignment between consecutive sections.  Following alignment, the 
newly transformed sections were then stacked and reconstructed into a 3D model of the 
heart.  Gap size (distance between two consecutive sections) and height (height of a section) 
were assigned manually.  Final parameters gap size= 10 and height parameter= 25.  The 
multiplier and spacing parameters were predetermined from the pixel size of the final 3D 
reconstruction, with the multiplier= 1, and spacing= 1, 1 and 5 along the x-, y-, and z-axes, 
respectively.  The data from the stacked, transformed images for each heart series were then 
written and compressed to a MHD file, which was visualized the VisualizeHistologyImage 
program.  Resulting 3D models were rotated and imaged at specific angles to allow for 
examination and comparison of cardiac morphology in different stages or conditions. 
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Figure 3.1. Histological sections of Xenopus hearts showing expression of myosin heavy
chain.
Wild-type embryos were transversely serial sectioned at stages 29 (a-c), 33 (d-f), or 37 (g-i).  
Shown are representative sections from the anterior-most, middle, and posterior regions of 
the heart tube, as indicated, at each stage.  Cardiac myosin heavy chain expression is shown 
in red.  Scale= 100µM.  TA= truncus arteriosis, OFT= outflow tract, V= Ventricle, SV= 
sinus venosus.   
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Figure 3.2. 3D models of Xenopus hearts based on myosin heavy chain expression reveal
dynamic MHC expression in the developing heart.
VisualizeHistologyImage program was used to generate 3D models of Xenopus hearts at 
stages 29 (a-c), 33 (d-f) or 37 (g-i) based on sections immunostained with myosin heavy 
chain.  The models are shown in anterior (a,d,g), dorsal (b,e,h), and lateral (c,f,i)  views, with 
orientation of axes is shown for each series at stage 29.  A section corresponding to the most 
anterior region of the heart is shown in red for each stage.  Arrowheads mark cardiac 
chambers. A= atrium, V= ventricle.  Arrows in panels b-i mark the outflow (O) and inflow 
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(I) tracts.  Orientation axis is shown for each series at stage 29 in the bottom right corner of 
the panel.  A= anterior, P= posterior, D= dorsal, V= ventral.  Scale= 50µM. 
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Figure3.3. 3D modeling of TBX5-depleted hearts reveals dynamic aspects of the cardiac
phenotype.
VisualizeHistologyImage program generated 3D models of Xenopus hearts from embryos at 
stages 29 (a-f), 33 (g-l), or 37 (m-r) injected with either control (CMO) or TBX5 
morpholinos (T5MO) as indicated.  3D models are shown in anterior (a,b,g,h,m,n), dorsal 
(c,d,i,j,o,p), or lateral (e,f,k,l,q,r) views, with orientation of axes shown for each series at 
stage 29.  Arrowheads mark cardiac chambers. A= atrium, V= ventricle.  Black arrows in 
panels i-j,o-p mark the outflow (O) and inflow (I) tracts.  Blue arrows indicate special 
features of the T5MO phenotype.  Axes are indicated in the top left panel of each grouping.  
A= anterior, P= posterior, D= dorsal, V= ventral.  Scale= 50 
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CHAPTER 4 
TBX5 is Required for Embryonic Cardiac Cell Cycle 
Progression 
 
PREFACE TO CHAPTER 4
Chapter 4 describes the requirement for TBX5 in cell cycle progression within the heart.  
Previously, it has been shown that TBX5 is required for proper heart development in 
vertebrates (Brown et al., 2005; Brunearu et al., 2001; Horb and Thomsen, 1999), and that 
the hearts of embryos lacking TBX5 are hypoplastic (Brown et al., 2005; Bruneau et al., 
2001).  Therefore, in this chapter we test the hypothesis that TBX5 is required for cardiac cell 
proliferation.  This work was performed in collaboration with Daniel Brown, and published 
in Development in 2006. 
 
SUMMARY 
Despite the critical importance of TBX5 in normal development and disease, relatively 
little is known about the mechanisms by which TBX5 functions in the embryonic heart. 
Our present studies demonstrate that TBX5 is necessary to control the length of the 
embryonic cardiac cell cycle, with depletion of TBX5 leading to cardiac cell cycle arrest 
in late G1 or early S phase. Blocking cell cycle progression by TBX5 depletion leads to a
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decrease in cardiac cell number, an alteration in the timing of the cardiac 
differentiation program, defects in cardiac sarcomere formation, and ultimately, to 
cardiac programmed cell death. In these studies we have also established that 
terminally differentiated cardiomyocytes retain the capacity to undergo cell division. 
We further show that TBX5 is sufficient to determine the length of the embryonic 
cardiac cell cycle and the timing of the cardiac differentiation program.  Thus, these 
studies establish a role for TBX5 in regulating the progression of the cardiac cell cycle. 
 
INTRODUCTION
Hyperplastic growth of the vertebrate heart is characterized by two distinct periods of 
proliferation, one that occurs during early embryogenesis and a second that takes place 
immediately following birth (MacLellan and Schneider, 2000; Olson and Schneider, 2003; 
Pasumarthi and Field, 2002). The embryonic phase of cardiac proliferation begins after 
cardiac cell commitment, and therefore occurs coincident with, or shortly after, gastrulation, 
a period when the cardiac precursor cells are positioned in two populations on both sides of 
the organizer or node. Once cells are committed into the cardiac lineage, the two populations 
of heart precursors migrate to assume their ultimate position along the anterior-ventral 
midline of the embryo. It is during this narrow window of time that the cardiac precursors 
undergo rapid cell proliferation to form two epithelial sheets that migrate and fuse, eventually 
forming the bilaminar heart tube (Fishman and Chien, 1997; Harvey, 2002; Kolker et al., 
2000; Mohun et al., 2003; Mohun et al., 2000). During the final stages of migration, the 
cardiac cells decrease DNA synthesis, gradually withdraw from the cell cycle, and initiate 
terminal differentiation (Pasumarthi and Field, 2002).  
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During the embryonic stage of cell proliferation, the cardiac cells express the first 
molecular markers of cardiac development, including Tbx5, Tbx20, and the homologue of the 
Drosophila tinman gene, Nkx2.5 (Harvey, 2002; Stennard and Harvey, 2005). Tbx5 is a 
member of the T-box family of transcription factors, a family of proteins that are required for 
normal vertebrate patterning and differentiation (Papaioannou and Silver, 1998; Showell et 
al., 2004; Stennard and Harvey, 2005; Wilson and Conlon, 2002). Clinical studies have 
provided direct evidence for a role for human Tbx5 in heart development, with Tbx5 
frequently mutated in patients with the congenital heart disease Holt-Oram Syndrome (HOS) 
(Basson et al., 1997; Li et al., 1997; Mandel et al., 2005).  HOS is a highly penetrant 
autosomal dominant condition that is associated with skeletal and cardiac malformations. The 
HOS cardiac developmental abnormalities include atrial and ventricular septal defects, as 
well as conductivity defects and aberrant chamber formation (Basson et al., 1999; Benson et 
al., 1996; Newbury-Ecob et al., 1996). A role for Tbx5 in HOS is supported by the 
observation that mice heterozygous for mutations in Tbx5 display many of the cardiac 
abnormalities associated with human patients suffering from HOS (Bruneau et al., 2001). 
Genetic studies of a Tbx5 mutation in zebrafish and TBX5 depletion in Xenopus are also 
consistent with a role for TBX5 in heart development (Brown et al., 2005; Garrity et al., 
2002; Horb and Thomsen, 1999). The evolutionarily conserved role for Tbx5 is further 
emphasized by molecular experiments carried out in tissue culture, zebrafish, Xenopus,
chicken, and mouse, all of which show a role for TBX5 transcriptional activity in regulating 
the expression of heart-specific genes (Brown et al., 2005; Bruneau et al., 2001; Garrity et 
al., 2002; Hatcher et al., 2001; Hiroi et al., 2001; Liberatore et al., 2000; Plageman and 
Yutzey, 2004). 
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Recently, we have shown that depletion of TBX5 in Xenopus leads to profound
morphological defects in the heart including pericardial edema, loss of circulation, and a
concomitant decrease in cardiac cell number (Brown et al., 2005). In the present study, we 
demonstrate that the observed decrease in cell number results from defects in embryonic
cardiac cell proliferation. We go on to define the expression pattern of an extensive panel of 
CDK and cyclin proteins in early embryonic cardiac tissue, and show that TBX5 depletion 
leads to a G1/S phase arrest as demonstrated by a dramatic increase in the expression of 
proteins associated with the cardiac cell cycle S phase including CDC6, cyclin E2, SLBP, 
and PCNA.  This suggests that TBX5 is involved in either G1/S phase or the early stages of S 
phase progression. The G1/S phase delay or arrest coincides with a decrease in the embryonic 
cardiac cell mitotic index. These events are associated with an alteration in the timing of the 
cardiac differentiation program, defects in cardiac sarcomere formation, and ultimately, 
cardiac programmed cell death. In contrast, over-expression of Tbx5, which we show also 
leads to heart-specific defects, results in an increase in the cardiac mitotic index and has a 
converse effect on the timing of the cardiac differentiation program. Collectively, these 
studies demonstrate that TBX5 is both necessary and sufficient to determine the length of 
cardiac G1/S phase and the timing of the cardiac differentiation program. 
 
MATERIALS AND METHODS
Embryo Culture and Microinjection 
Xenopus embryos and Xenopus Cardiac Actin:GFP transgenic offspring (Latinkic et al., 
2002) were prepared and injected as previously described (Wilson and Hemmati-Brivanlou, 
1995), and staged according to Nieuwkoop and Faber (Nieuwkoop, 1967).  For TBX5 
depletion studies, embryos were injected with TBX5 and CMO morpholinos as per Brown et 
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al. (Brown et al., 2005).  In mis-expression studies, capped mRNA for microinjections was 
generated using the mMessage in vitro transcription kit (Ambion) according to the 
manufacturer’s instructions.  Resulting mRNA was then purified using the RNeasy kit 
(Qiagen).  Embryos were injected with the stated amount of Tbx5 RNA  at the one cell stage.  
Transgenic animals expressing GFP under the cardiac actin promoter were a gift from Dr. 
Tim Mohun (Latinkic et al., 2002). 
 
Immunohistochemistry and Whole-Mount in situ Hybridization 
Embryos were prepared for whole-mount immunohistochemistry according to (Kolker et al., 
2000).  Briefly, fixed embryos were incubated overnight at 4 ºC with an antibody against 
tropomyosin, (Developmental Studies Hybridoma Bank) at a dilution of 1:50.  Following 
washes, the embryos were incubated overnight at 4ºC with a Cy3-conjugated anti-mouse 
secondary antibody (Sigma) at a dilution of 1:100.  For imaging, embryos were cleared with 
2:1 benzyl benzoate: benzyl alcohol and viewed on a Leica MZFLIII fluorescent dissecting 
microscope.  For immunostaining of histological sections, embryos were collected at the 
indicated stages, fixed for 2 hours in 4% paraformaldehyde, and embedded in OCT 
cryosectioning medium (Tissue Tek).  Cryostat sections (14um) were rinsed with wash buffer 
(PBS with 1% Triton and 1% heat inactivated calf serum), and incubated at 4 ºC overnight as 
indicated with mouse anti-tropomyosin 1:50, mouse anti-troponin 1:20, mouse anti-fibrillin 
1:50, (all from Developmental Studies Hybridoma Bank); mouse anti-MHC (Abcam) rabbit 
anti-fibronectin 1:50 (Sigma), rabbit anti- Beta-catenin all at 1:1000 (Sigma), rabbit anti-
phospho-histone H3 1:50 (Upstate), rabbit anti-cleaved Caspase 3 1:50 (Cell Signaling).  The 
sections were rinsed with wash buffer and the appropriate fluorescent conjugated secondary 
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antibody diluted in wash buffer:  anti-mouse-Cy3 1:100 (Sigma), anti-mouse Cy2 1:100 
(Jackson), anti-rabbit-Cy3 1:100 (Sigma), anti-rabbit-FITC 1:150 (Sigma).  Samples were 
incubated 30 minutes at room temperature with DAPI (Sigma) to stain nuclei, or phalloidin 
conjugated to Alexa 488 (Molecular Probes, 1:1000) to stain actin filaments.  The samples 
were imaged on a Zeiss LSM410 confocal microscope.  Whole-mount in situ hybridization 
was performed as previously described (Harland, 1991). 
 
RT-PCR 
RNA was extracted from homogenized embryos at the indicated stages (five embryos per 
condition) using the RNeasy (Qiagen) kit according to the manufacturer’s instructions.  
cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen). PCR reactions 
with Taq polymerase were performed according to established protocol using 1ul of the 
resulting DNA.  (See Supplemental Data for primer sequences and a detailed protocol).  
 
Western Blots 
Heart tissue from a minimum of 300 embryos per condition was dissected at stage 33 and 
snap frozen.  Tissue was homogenized, subjected to SDS-PAGE, and transferred according 
to established protocols.  Blots were probed overnight at 4 QC with antibodies against Cdc6, 
Cdt1 (gift from M. Coué, both 1:500 (Whitmire et al., 2002)), cyclin E2 (Abcam, 1:500), 
PCNA (Zymed, 1:1000), MCM 4 (Abcam, 1:2000), MCM 5 (Abcam 1:400), MCM7 
(LabVision, 1:200), Cdk1 (Zymed, 1:1000), Cdk2 (Upstate, 1:1000), cyclin A1, cyclin A2 
(Abcam, both 1:1000), SLBP (gift from W. Marzluff, 1:1000 (Wang et al., 1999)), and cyclin 
B2 (gift from T. Hunt, 1:500 (Hochegger et al., 2001)).  Blots were rinsed and probed with 
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the appropriate HRP-conjugated secondary antibody (Jackson, 1:10000), and detected with 
ECL.  As a loading control, blots were reprobed with antibodies against Total MEK (Cell 
Signaling, 1:2000), alpha tubulin (Abcam, 1:1000), and/or SHP2 (BD Biosciences, 1:2500). 
 
Transmission Electron Microscopy 
Stage 37 embryos were fixed in 2% paraformaldehyde/2.5% gluteraldehyde overnight.  
Embryos were post-fixed in ferrocyanide-reduced osmium and embedded in Spurr’s epoxy 
resin.  Transverse ultrathin (70 nm) sections were mounted on copper grids, and post-stained 
with 4% aqueous uranyl acetate followed by Reynolds’ lead citrate.  Sections were imaged 
with a LEO EM-910 transmission electron microscope. 
 
RESULTS
TBX5 depletion leads to a decrease in cardiac proliferation 
To understand the role of TBX5 in heart development, we depleted TBX5 from Xenopus
embryos using a morpholino-based approach. Results from these studies show that removal
of TBX5 leads to morphologically abnormal hearts and a decrease in cardiac cell number that
is not associated with a block in cardiac specification, commitment, migration, or
differentiation (Brown et al., 2005); (Fig. 4.1A,B). To characterize the phenotype of TBX5-
depleted embryos in more detail, and to determine the precise developmental stage at which
TBX5 is required during cardiogenesis, we carried out histological analyses and cell counting
studies in TBX5 morpholino-injected (T5MO) and Control morpholino-injected (CMO)
embryos by double-staining for the cardiac and skeletal muscle marker tropomyosin and with
DAPI, to mark cell nuclei (Fig. 4.1C-F). All cells throughout the heart for each stage were
counted, and quantitative results are reported in Fig. 4.1S. There was no significant
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difference between control and TBX5-depleted embryos at stage 33 (Fig. 4.1C,E,S).
However, at stage 37 T5MO embryos show a significant decrease in cardiac cell number
compared with their sibling controls (Fig. 4.1D,F,S). The defect in cell number precedes the
expression of proposed TBX5 target genes including atrial naturitic factor (ANF/Nppa) and
connexin 40 (Bruneau et al., 2001; Hiroi et al., 2001; Small and Krieg, 2000). Therefore, the
reduction in cardiac cell number appears to be one of the primary cardiac defects in TBX5-
depleted embryos.
To determine if the decrease in cardiac cell number is due to cell proliferation or
programmed cell death, we analyzed the mitotic index (Fig. 4.1G-L,T) and apoptosis (Fig.
4.1M-R, U) at defined time points during heart development: stage 29, which corresponds to
the stage when the heart field rounds up to begin forming the bilaminar heart tube; stage 33,
at which time cardiac looping is initiated; and stage 37, corresponding to early chamber
formation. For these studies CMO and T5MO embryos at each stage were serial-sectioned
through the cardiac regions and triple immuno-stained with anti-tropomyosin (Tmy) to mark
cardiomyocytes, DAPI to mark cell nuclei, and either anti-phospho histone H3 (pH3) to mark
cells in M phase (Fig. 4.1 G-L), or anti-cleaved Caspase 3 to mark cells undergoing apoptosis
(Fig. 4.1 M-R). In each study all cardiomyocytes and endocardial cells encompassed by the
cardiomyocytes for each heart at each stage were scored for pH3 or cleaved Caspase 3.
CMO embryos show that the total cardiomyocyte cell numbers undergo a doubling
every 4 stages, or 9 hours, at room temperature between stages 33 and 37 (Fig. 4.1 G-I, M-
O). Since the majority of the cardiomyocytes appear to be undergoing mitosis (based on
serial sections of multiple embryos at these stages), the embryonic cardiac cell cycle in
Xenopus is approximately 9 hours in length with M phase lasting approximately 20 minutes,
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with the mitotic index gradually decreasing with age (Fig. 4.1T). We note there is little to no
cardiomyocyte programmed cell death during these stages (Fig. 1U).
Results from these studies clearly show a decrease in the mitotic index of T5MO-
derived embryos relative to CMO embryos at stage 33 (Fig. 4.1T), however, no significant
programmed cell death was observed until later stages (stage 37; Fig. 4.1U). Since we
observe a dramatic decrease in the mitotic index at a time prior to the decrease in cardiac cell
number or increases in cardiac programmed cell death (Fig. 4.1S-U), the primary cause of the
reduction in cell number in T5MO cardiac tissue appears to be a decrease in cardiac cell
proliferation. Taken together, the data suggests that the decrease in proliferation resulting
from depletion of TBX5 is due to either a lengthening of the embryonic cardiac cell cycle or
alternatively, a premature exit of cardiomyocytes from cell cycle.
TBX5 depletion leads to a cardiac cell cycle delay or arrest in G1/S phase  
Inference from other systems implies that the integration of growth factor signal cascades
with G1/S cell cycle passage is regulated by the cyclin/CDK complexes CDK2/cyclin E,
CDK2/cyclin A, and CDK1/cylin D, many of which are expressed in Xenopus in a stage- and
tissue-specific fashion (Vernon and Philpott, 2003). Although much is known about the
cardiac cell cycle during neonatal periods, little is known about the expression of CDKs and
cyclins during the early stages of embryonic heart development. To address this issue, we
isolated hearts from the first stage at which we could anatomically isolate pure cardiac tissue
(stage 33). The resultant tissues were analyzed relative to corresponding whole embryo
lysates with an extensive panel of antibodies specific for individual cyclins and CDKs (Fig.
4.2A). Results from this analysis show that Xenopus cardiac tissue at stage 33 expresses
cyclin E2, CDC6, PCNA, SLBP, CDK2, cyclin A2 and CDK1, as well as proteins that are
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expressed uniformly throughout the cell cycle such as MCM4 and MCM7. Although we
could detect high levels of CDT1, cyclin A1, cyclin B2, and MCM5 in stage 33 embryos, we
were able to detect little to no expression of these proteins in the heart (Fig. 4.2A). However,
due to the relative amount of cardiac tissue to that of whole embryos, we cannot formally
rule out the possibility that these proteins are present at relatively lower amounts. We note
that we were unable to identify any antibody that marked D cyclins in Xenopus. However,
previous studies have suggested that neither of the Xenopus D cyclins, cyclin D1 or D2, are
expressed in the heart at these stages (Vernon and Philpott, 2003).
We next analyzed cell cycle proteins in heart tissue derived from T5MO and CMO
embryos (Fig. 4.2B). These studies show that depletion of TBX5 leads to a dramatic up-
regulation of S phase proteins cyclin E2, CDC6, and CDK2 while proteins associated with
other cell cycle phases, cyclin A2 and CDK1, or proteins expressed throughout the cell cycle,
such as MCM4 and MCM7, show no significant differences between T5MO- and CMO-
derived heart tissues (Fig. 4.2B). Together with the mitotic index data, our results strongly
suggest that depletion of TBX5 leads to a prolonged/arrested G1 or S phase and a
concomitant decrease in the proportion of cardiac cells in M phase.
To confirm these findings we also analyzed CMO- and T5MO-derived hearts for the
non-CDK/cyclin S phase proteins stem loop binding protein (SLBP) and proliferating cell
nuclear antigen (PCNA) (Fig. 4.2C). Western blots of CMO- and T5MO-derived heart tissue
show that relative to the loading controls SHP2 and total MEK, depleting TBX5 leads to an
increase in both SLBP and PCNA levels. Collectively, these results strongly suggest that
TBX5 depletion leads to a delay or block in the G1 or S phase of the cardiac cell cycle.
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Terminally differentiated cardiomyocytes continue to undergo cell division 
Our results suggest that TBX5 is required for embryonic cardiac cell cycle progression (Fig. 
4.2) but is not required for cardiac differentiation (e.g. Fig. 4.1A,B). Thus, terminally 
differentiated cardiomyocytes could be undergoing cell division or, alternatively, a 
subpopulation of Xenopus cardiomyocytes may undergo cell cycle arrest and terminal 
differentiation while a second subpopulation of cardiomyocytes continue to divide and 
remain in an undifferentiated state. The former is consistent with studies in chick and mouse 
which imply that heart tissue is capable of initiating and maintaining terminal differentiation 
during a period in which the cells are still dividing; i.e. not during G1 or G0 arrest  (Anversa 
and Kajstura, 1998; Burton et al., 1999; Kajstura et al., 2004; McKinsey et al., 2002; Mikawa 
et al., 1992; Mikawa et al., 1992; Rybkin et al., 2003; Soonpaa and Field, 1998). To directly 
test the relationship between the cardiac cell cycle and terminal differentiation in Xenopus 
embryonic cardiac tissue, we triple-labeled cardiomyocytes at stage 37 with anti-pH3, DAPI, 
and a panel of antibodies that detect terminally differentiated cardiomyocytes including anti-
tropomyosin (Tmy), anti-myosin heavy chain (MHC), and phalloidin, to mark cardiac actin 
(Fig. 4.3).  Results from these studies clearly show that in CMO hearts we are able to detect 
cardiomyocytes that are undergoing mitosis yet also co-express all three markers of terminal 
differentiation (Fig. 4.3A-D). In addition, we note that cardiomyocytes expressing 
tropomyosin, cardiac actin, and cardiac myosin heavy chain, show the hallmarks of terminal 
cardiomyocyte differentiation including the assembly of cells into muscle fibers containing 
A- and Z-bands. Consistent with findings that fewer cardiac cells in T5MO embryos undergo 
mitosis (Fig. 4.1), we were able to detect very few anti-phosphorylated histone H3 positive 
cells in T5MO-derived hearts. However, of the few cells that expressed pH3, these cells, like 
105
controls, also co-expressed markers of cardiomyocyte terminal differentiation, including 
tropomyosin, actin, and myosin heavy chain (Fig. 4.3E-H). Taken together, these data 
indicate that terminally differentiated cells in both control and TBX5-depleted embryos 
retain the capacity to undergo cell division and suggest that Xenopus cardiac cells during 
these stages do not arrest in G1 or G0. These data further suggest that TBX5, although 
required for cardiac cell cycle progression, is not required to initiate or maintain cardiac 
differentiation.  
 
TBX5 is required for the proper timing of the cardiac program 
Since TBX5 depletion does not block cardiac differentiation, we next addressed whether 
TBX5 depletion could affect the stage at which cardiac markers are initially expressed. To
this end, we collected equivalently staged T5MO and CMO embryos at all early stages at
which Tbx5 has been reported to be expressed: stages 10 through 38 (early gastrula through
late tadpole). In the first series of studies, we carried out RT-PCR with a panel of primers
specific for markers of cardiac differentiation (cardiac myosin heavy chain, cardiac troponin,
and tropomyosin) or skeletal muscle differentiation (MyoD, skeletal muscle actin) (Fig.
4.4A). Results show significant differences in the timing of cardiac gene expression in
T5MO embryos relative to their stage-matched CMO siblings; T5MO embryos turn on
troponin and cardiac myosin heavy chain (MHC) at earlier stages than controls (stage 28 in
T5MO versus stage 32 in CMO) but initiate expression of Tmy at later stages (stage 24 in
T5MO versus 22 in CMO). Since we do not observe any changes in the timing at which
skeletal muscle markers are expressed, the alteration in timing of differentiation appears to be
specific to cardiac tissue.
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To confirm these findings, we carried out whole-mount antibody staining on T5MO
and CMO embryos for tropomyosin. Consistent with the RT-PCR analysis, we observe a
delay in the expression of tropomyosin in T5MO embryos in comparison to CMO embryos
(Fig. 4.4 B-I). As further confirmation that the timing of differentiation is altered in response
to TBX5 depletion in vivo, we injected embryos carrying the cardiac actin:GFP transgene
(Latinkic et al., 2002) with T5MO or CMO and monitored skeletal muscle and heart
development in living staged-matched embryos (Fig. 4.4J-Q). Although we could not detect
any alteration in the timing of GFP expression in skeletal muscle (data not shown), we
observed a consistent and significant delay in the time at which GFP was first expressed in
the hearts of the T5MO embryos. Collectively, these results suggest that control of the
cardiac cell cycle by TBX5 leads to an alteration in the timing of the cardiac program.
TBX5 depletion leads to abnormal sarcomere formation 
To determine if cardiomyocyte differentiation in T5MO hearts occurs in all cardiomyocytes
or only in a subset of cells, we analyzed cardiomyocyte differentiation by
immunohistochemistry on cross-sections of CMO and T5MO-derived tissues (Fig. 4.5A-H).
Results clearly show that by stage 37, we can detect staining of troponin T (cTnT), MHC,
and Tmy throughout the myocardium of control and T5MO hearts, suggesting that all
cardiomyocytes in T5MO undergo terminal differentiation.
To examine sarcomere and cytoskeletal structure in greater detail, we double- labeled
hearts from CMO and T5MO embryos with the cardiomyocyte marker Tmy and antibodies
that recognize either components of the cardiac extracellular matrix (ECM): fibronectin and
fibrillin, or mark cardiomyocyte polarity, -catenin (Fig. 4.5I-N); (Trinh and Stainier, 2004).
This analysis revealed that TBX5 depletion leads to hearts with defects in both sarcomere
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and ECM development. In contrast to CMO-derived hearts, which form sarcomeres
throughout the myocardium, T5MO hearts only form sarcomeres in cells adjacent to the
lumen of heart (Fig. 4.5G-J,O,P). Moreover, the sarcomeres that form often lack A- and Z-
bands and frequently fail to give rise to myofibrils (Fig. 4.5O, P). These alterations in
cardiomyocyte differentiation coincide with elevated fibronectin deposition particularly
within the dorsal portion of the T5MO in dorsal regions where the heart remains unfused
(Fig. 4.5I,J) and an increase in both fibronectin and fibrillin deposition on the walls of the
heart chamber (Fig. 4.5I-L). However, we could detect no alteration in -catenin expression
(Fig. 4.5M,N). We also note that at this stage, it appears the majority of -catenin is
associated with the myocardial membranes with little to no -catenin in the cytoplasm or
nucleus. Taken together this data suggests that alteration in cardiac cell cycle progression due
to the depletion of TBX5 leads to abnormal cardiomyocyte and ECM maturation.
To confirm these structural alterations in TBX5-depleted heart tissue, we carried out
ultrastructure analyses on CMO and T5MO hearts by high magnification confocal
microscopy (Fig. 4.5O,P) and transmission electron microscopy (TEM) (Fig. 4.5Q-V). High
magnification imaging of cardiac tissue immunostained with Tmy reveals that cardiac cells in
CMO embryos form myofibrils that are distributed throughout the myocardium (Fig. 4.5O).
In contrast, myofibrils in T5MO cardiac cells are poorly organized and form only adjacent to
the cardiac lumen (Fig. 4.5P).
Consistent with immunostaining for cardiac muscle, we find in transverse TEM
sections of CMO embryos that cardiac muscle bundles are located throughout the
myocardium, positioned in both longitudinal as well as concentric arrays (Fig. 4.5Q). In
contrast, T5MO hearts show far fewer sarcomeres than controls, and the cells bordering the
pericardial space of T5MO hearts, in contrast with those bordering the heart lumen,
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completely lack bundles of cardiac muscle fibers (Fig. 4.5R,S,V). Moreover, the sarcomeres
that form frequently lack distinct A- and Z-bands, and the A- and Z-bands that are present are
poorly defined (Fig. 4.5T,U). This does not appear to represent simply a delay in myofibril
formation since during normal development myofibrils form throughout the myocardium and
do not show any temporal differences in differentiation between distal and proximal
cardiomyocytes (Kolker et al., 2000; Langdon, et al., submitted).
Taken together, our immunohistochemistry and ultrastructure analysis suggest that
the G1/S phase delay or arrest in TBX5-depleted embryos results in an alteration in the
timing of the cardiac program leading to asymmetric and aberrant sarcomere formation.
Moreover these results imply that TBX5 is not required for the onset of cardiac
differentiation but is required to either establish or maintain cardiomyocyte and cytoskeletal
architecture.
TBX5 is both necessary and sufficient for the progression of the embryonic cardiac cell 
cycle 
Our analysis of T5MO embryos shows a requirement for TBX5 in embryonic cell cycle
progression and a role in controlling the correct timing of cardiac differentiation. To
determine if TBX5 is sufficient to regulate these two processes, we mis-expressed Tbx5 in
early Xenopus embryos (Fig. 4.6). Although injection of Tbx5 RNA at the single cell stage
causes Tbx5 mis-expression throughout the embryo, phenotypic abnormalities are restricted
to the anterior and cardiac regions of the early tadpole (Fig. 4.6A-C, data not shown). To
further analyze these defects, we carried out whole-mount in situ hybridization analyses on
uninjected control and Tbx5-injected embryos (Fig. 4.6D-G; data not shown). Similar to
results from TBX5 depletion, this analysis shows Tbx5 mis-expression does not block cardiac
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commitment, migration, or terminal differentiation as judged by Nkx2.5 and Myosin Light
Chain (MLC) expression (Fig. 4.6D-G).
To test if Tbx5 cardiac defects are associated with alteration in the cardiac cell cycle,
we serial sectioned embryos at stage 37 and stained with the mitotic marker anti-pH3. We
found that Tbx5 mis-expression has the opposite effect of depleting TBX5, leading to a two-
fold increase in the cardiac cell mitotic index (Fig. 4.6H).
To ensure that the increase in mitotic index is tissue specific, we calculated the 
mitotic index in the ventricular zone of the neural tube in the same sections as those 
containing the heart tissue; i.e. sections that correspond exactly to the same point along the 
anterior-posterior axis. We could not detect a difference between control or Tbx5 mis-
expressing derived neural tissue. Therefore, the increase in mitotic index within appears to be 
cardiac specific. 
To test whether TBX5 is also sufficient for the correct timing of cardiac 
differentiation, we again collected stage-matched embryos from stage 10 to stage 38 and 
carried out RT-PCR with primers specific for the early cardiac marker Nkx2.5, and for 
markers of cardiac and skeletal muscle differentiation (Fig. 4.6J).  Consistent with our results 
for the in situ hybridization experiment, we found no alteration in Nkx2.5 expression in Tbx5 
injected embryos.  Results for the cardiac differentiation markers show the exact opposite of 
those for TBX5 depletion; Tbx5 injected embryos initially express Troponin and MHC at 
later stages than controls (stage 38 in Tbx injected versus stage 28 in control embryos) but 
turn on Tmy at earlier stages (stage 16 in Tbx5 injected versus 22 in control embryos).  Since 
we do not observe any changes in the timing at which skeletal muscle markers are expressed, 
the alteration in timing of expression again appears to be specific to cardiac tissue. 
Collectively, these studies strongly suggest that TBX5 is both necessary and sufficient to 
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regulate progression of the embryonic cardiac cell cycle and the timing of the cardiac 
program.  
 
DISCUSSION
Despite the critical importance of understanding cell cycle control for both normal 
development and disease, relatively little is known about the proteins that regulate these 
processes in the embryonic heart. We demonstrate that that TBX5 is both necessary and 
sufficient to control embryonic cardiac cell proliferation and cell number by regulating the 
length of the embryonic cardiac cell cycle. Our results show that depletion of TBX5 leads to 
a delay or arrest in G1 or S phase as judged by the up-regulation of the G1/S phase-associated 
proteins and the concomitant decrease in the cardiac mitotic index. If the arrest was occurring 
at the S/G2 transition, Cdc6 and Cyclin E2 levels should be equivalent between T5MO and 
control heart tissue. Moreover, cyclin A2 and Cdk1 should be significantly elevated in the 
T5MO hearts. Since our results clearly show that the level of neither protein is altered in the 
T5MO tissue relative to the control our data strongly suggest that the arrest does not occur at 
S/G2 but at the G1/S phase transition. Since cyclins E and A are thought to be expressed 
sequentially during S phase, and since we observe an increase in cyclin E2 but not in cyclin 
A2, our results would predict that S phase arrest in TBX5-depleted embryos occurs at the 
G1/S transition or in early S phase. Based on these findings, we propose that depleting TBX5 
results in a prolonged or blocked early S phase resulting in fewer rounds of proliferation, in 
turn leading to the reduced cardiac cell number we observe in T5MO embryos (Fig. 4.7).  
Past studies have implied that the myocardium undergoes a fixed number of
intrinsically determined cell divisions before entering a post-mitotic state and undergoing
cardiac differentiation (Burton et al., 1999). It appears that TBX5 interferes with this
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autonomous program by forcing cells into a prolonged or arrested S phase and thus,
differentiating without undergoing a predetermined number of cell divisions. Since in the
TBX5-depleted embryos and embryos mis-expressing Tbx5 the timing of the cardiac
differentiation program is altered compared to controls, our results imply that proper S phase
progression and possibly a determined number of divisions, are required for the proper
timing, but not the initiation, of heart differentiation. Our results further imply that a reduced
number of cardiac divisions leads to a delay in the expression of some markers of terminal
differentiation including cardiac actin, and tropomyosin. In contrast, we note that troponin
and MHC are expressed earlier in T5MO cardiac tissue and later in hearts from embryos
mis-expressing Tbx5 suggesting that these markers are controlled in a different fashion
relative to other cardiac terminal markers.
TBX5 and embryonic cardiac cell cycle control 
Like other members of the T-box gene family, TBX5 has been shown to function as a
transcription factor; TBX5 is localized to the nucleus, it binds to DNA in a sequence specific
fashion, and regulates the transcriptional level of its target genes. Our present studies suggest
that at least one of the targets of TBX5 either directly or indirectly functions to control the
progression of the embryonic cardiac cell cycle. What are the mechanisms by which this may
occur? One possibility is that TBX5 could function to induce the expression of a growth
factor, for example EGF or FGF, which in turn is required for cell cycle progression. In the
absence of this growth factor the cell cycle may not proceed through to the completion of G1
(Fig. 7). Alternatively, TBX5 may function to regulate the expression of a key component of
the pre-replication complex. In the absence of this key component the pre-replication
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complex may not assemble or may not load onto the origins of replication (ORCs) thus,
blocking DNA synthesis and hence cell cycle progression (Fig. 4.7).
Cell cycle progression through G1/S is regulated by members of the E2F family of 
transcription factors, whose function is governed through their interaction with the 
retinoblastoma protein (Rb). In its hypophosphorylated state Rb interacts with E2F inhibiting 
its transcriptional activation activity. Upon Rb phosphorylation, the Rb-E2F interaction is 
disrupted and E2F is released and able to activate its downstream genes required for S phase 
entry (Cobrinik, 2005). Thus, one function of TBX5 may be to indirectly regulate the state of 
pRB phosphorylation. Finally, TBX5 may function to negatively regulate general cell cycle 
inhibitors such as p27Xic (Fig. 4.7). Our data cannot distinguish between these possibilities
and the exact molecular pathway by TBX5 functions awaits the identification of TBX5 cell
cycle target genes.
Tbx5 mis-expression leads to cardiac-specific defects 
We show that mis-expression of Tbx5 leads to cardiac defects in vivo. This effect appears to
be specific since mis-expression of other T-box containing genes does not give a similar
phenotype (Showell et al., 2004). These results demonstrate that the absolute levels of TBX5
are critical for normal heart development in vivo; increased levels of TBX5 result in
abnormal heart formation and reduction of TBX5 levels by just half leads to HOS.
Interestingly, the defects we observe with Tbx5 mis-expression are specific to the anterior
and cardiac regions of the embryo, with the cardiac defects resembling those seen with
Nkx2.5 mis-expression (Cleaver, 1996; Tonissen et al., 1994). The similarity between the
Tbx5 and Nkx2.5 over-expression phenotypes raises the possibility that mis-expression
phenotype we observe in TBX5 is due to an up-regulation of Nkx2.5. However, a number of 
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our findings would suggest this is not the case. Most critically, we have conducted in situ 
hybridization as well as RT-PCR to examine Nkx2.5 expression in embryos mis-expressing 
Tbx5 during early stages of early heart development.  We show that mis-expression of TBX5 
does not lead to altered spatial or temporal patterns or levels of Nkx2.5 expression at any 
stage. These results are consistent with our previously published results showing that the loss 
of TBX5 has no effect on the temporal or spatial expression of Nkx2.5 (Brown et al., 2004). 
Therefore, mis-expression of Tbx5 appears to alter the cardiac mitotic index in an Nkx2.5 
independent fashion. 
Our finding that Tbx5 mis-expression results in an increased mitotic index differs
from two previous studies implying that Tbx5 expression inhibits cell growth or survival
(Hatcher et al., 2001; Liberatore et al., 2000). However, in these reports Tbx5 was mis-
expressed after expression of endogenous Tbx5 is initiated and consequently, after the
commitment and differentiation of the heart have taken place. Thus, it may be possible that
TBX5 has two opposing functions during development: an early function in regulating
cardiac cell cycle progression and a late function instructing cardiac cells to undergo cell
cycle arrest. Alternatively, over-expression of TBX5 may lead to it binding and activating
non-endogenous targets, in particular those of other T-box gene genes, such as TBX2, TBX3,
TBX18, or TBX20 (Harvey, 2002; Stennard and Harvey, 2005), which may function during
the later stages of cardiogenesis to regulate cell cycle exit.
Holt Oram syndrome 
HOS is an autosomal dominant disease arising from haploinsufficiency of TBX5 and is 
associated with conduction-system abnormalities, secundum atrial defect (ASD), and 
ventricular septal defects (VSD) (Basson et al., 1997; Li et al., 1997; Newbury-Ecob et al., 
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1996).  Consistent with these phenotypic abnormalities, Tbx5 has been shown to be 
expressed in the atrial wall, the atrial septa and the atrial aspects of the atrioventricular valves 
(Hatcher et al., 2000).  The role of TBX5 in heart development is further emphasized by the 
observation that mice heterozygous for mutations in Tbx5 display many of the abnormalities 
described in HOS patients (Bruneau et al., 2001).  However, the cellular basis for defects in 
HOS remains unclear. Our results would suggest that TBX5 functions to regulate the length 
of the G1/S cycle within the subset of heart tissues in which it is expressed.  In HOS, G1/S 
phase would be significantly lengthened or blocked, leading to a decrease in cell cycle 
progression and defects in cell proliferation due to a successive decrease in the number of 
cell divisions, and ultimately programmed cell death in the affected regions.  
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Figure 4.1. TBX5 is required for cardiac proliferation.
Whole-mount antibody staining with trypomyosin (Tmy) of stage 37 (A) control morpholino 
(CMO) or (B) TBX5 morpholino (T5MO) embryos (a, atrium; v, ventricle; i, inflow tract; o, 
outflow tract). Transverse heart sections through (C, E) stage 33 and (D, F) stage 37 
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embryos stained with Tmy, to mark cardiac tissue, and DAPI, to mark cell nuclei, (C, D) 
CMO-derived tissue, (E, F) T5MO-derived tissue.  (G-L) Examples of proliferating cardiac 
cells in transverse heart sections from (G-I) CMO and (J-L) T5MO embryos sectioned 
through the cardiac region at stage 29, 33, and 37, as indicated.  Proliferating cardiomyocytes 
are identified as those positive for Tmy (myofibrilis shown as green) and anti-phopho-histone 
H3 (pH3; localized to the nucleus and shown in red).  (M-R) Examples of cardiac cells 
undergoing apoptosis in transverse heart sections from (M-O) CMO and (P-R) T5MO 
embryos at stage 29, 33, and 37, as indicated.  Apoptotic cardiomyocytes are identified as 
those positive for Tmy (myofibrilis shown as green) and anti-cleaved caspase 3 (CC3; 
localized to the nucleus and shown in red).  Quantification of results from (S) total 
cardiomyocyte cell numbers, (T) mitotic index, and (U) programmed cell death.  In all cases, 
bars represent the average of at least 3 embryos.   CMO, red bar and T5MO, blue bar.  Error 
bars denote the standard deviation and * denotes a statistically significant difference (at p 
<0.05) between CMO and T5MO embryos at a given stage. (Scale bars = 50 µm).  Results 
are derived from a single set of experiments, all experiments being repeated at least once 
with an independent batch of embryos. 
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Figure 4.2. TBX5 depletion results in dramatic up-regulation of proteins associated with
G1/S phase within the heart.
(A) Expression profile of cell-cycle associated proteins as determined by Western blot 
analysis performed using lysate from either whole stage 33 embryos (emb), or corresponding 
heart tissue (heart).  (B) Relative differences in embryonic cardiac CDK and cyclin proteins 
between CMO and T5MO-derived heart tissue (stage 33). Note increased levels of Cyclin 
E2, CDC6, CDK2.  (C) Relative differences in embryonic cardiac S-phase associated 
proteins SLBP and PCNA between CMO and T5MO-derived heart tissue (stage 33).  
Colored bars denote the stage of the cell cycle at which the proteins are expressed, as 
indicated in the key. 
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Figure 4.3. Terminally differentiated cardiomyocytes retain the capacity to undergo cell
division.
Transverse sections of (A-C) CMO or (E-G) T5MO heart tissues at stage 37, showing cells 
co-expressing pH3 (red), DAPI (blue), and either (A, E) actin, (B, F) Tmy, or  (C, G) MHC 
(all shown in green).  (D) Schematic of a CMO heart displaying the relative positions of each 
panel.  (A) and (B) were imaged from an area corresponding with ‘A,B’; (C) was imaged 
from a region corresponding with ‘C’ (a, atrium; v, ventricle).  (H) Schematic of a T5MO 
heart displaying the relative positions of each panel.  (E) corresponds with ‘E’; (F) and (G) 
correspond with ‘F,G’.  White arrows denote sarcomeric bundles (Scale bar = 10 µm). 
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Figure 4.4. The timing of the cardiac differentiation program is altered in TBX5 depleted
embryos.
(A) RT-PCR analysis of the expression of heart-specific isoforms of MHC, troponin, and 
tropomyosin; and skeletal muscle-specific genes MyoD and muscle actin, throughout early 
and mid-gestation stages of development in CMO (“C”) and T5MO (“T”) staged matched 
embryos.  All samples are derived from a single batch of eggs and identical results were 
achieved in at least two independent sets of experiments for each marker. EF1-Alpha was 
used as a loading control for all RT-PCR reactions.  (B-I)  Images depicting embryos injected 
with (B-E) CMO, or (F-I) T5MO and immunostained for Tmy showing delayed expression 
of Tmy in the hearts of T5MO embryos.  Shown are representative sibling embryos imaged 
at the indicated stages.  White arrows denote expression of Tmy within the heart.  (J-Q)  
Images of living cardiac actin:GFP transgenic embryos showing a delay in the onset of 
cardiac actin expression in the heart.  Representative sibling embryos obtained from a single 
batch of embryos were injected with (J-M) CMO or (N-Q) T5MO and imaged at the 
indicated stages. Shown is a representative pair of embryos, while identical results were 
observed in over 50 embryos. White arrows denote expression of GFP within the heart field. 
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Figure 4.5. TBX5 depletion leads to a disruption in cardiac myofibril structure.
Cardiomyocyte structure in transverse sections through the hearts of  (A, C, E, G) CMO or 
(B, D, F, H) T5MO stage 37 embryos as detected by immunostaining for (A, B) cardiac 
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troponin T (cTNT), (C, D) MHC, (E, F) actin, or (G, H) Tmy (scale bar = 50 µm). (I, K, M) 
Stage 37 CMO or (J, L, N) T5MO embryos double-immunostained for tropomyosin (green) 
and (I, J) fibronectin, (K, L) fibrillin, or (M, N) W-catenin, all shown in red (scale bar = 50 
µm).  Note increase in fibrillin staining on the walls of the chamber of T5MO hearts relative 
to CMO (compare panel K to L, white arrows) and ectoptic expression of fibronectin, shown 
by white arrow, in the dorsal portion of the heart in panel J relative to panel I. (O, P) High 
magnification confocal images of hearts from (O) CMO or (P) T5MO stage 37embryos.  
Note that formation of organized cardiac muscle bundles in T5MO hearts is limited to a 
single cluster adjacent to the cardiac lumen.  (Q-S) Representative transmission electron 
micrographs of transverse images of stage 37 embryos taken from (Q) CMO cardiac tissue or 
(R) T5MO cardiac tissue adjacent to the pericardial cavity and (S) T5MO cardiac tissue 
adjacent to the cardiac lumen. Cardiac muscle fibrils are shown pseudo-colored in yellow.  
(Scale bars = 2 µm).  Note that sarcomeres in T5MO hearts can only be identified adjacent to 
the cardiac lumen (compare R to S) and only found in concentric arrays.  In contrast, CMO-
derived hearts show both longitudinal as well as concentric arrays (compare Q to S).  High 
magnification TEM images reveal the ultrastructures of (T) CMO and (U) T5MO cardiac 
sarcomeres.  Arrows denote A-bands.  Note the smaller, non-continuous A-bands in the 
T5MO-derived sarcomeres (U) (scale bar = 0.2 µm).  (V) Traces of the heart sections from 
CMO and T5MO embryos imaged by TEM are depicted schematically.  Yellow circles 
represent the location of TEM imaging. 
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Figure 4.6. Tbx5 mis-expression leads to changes in cardiac proliferation and
morphology.
The overall morphology of stage 40 (A) uninjected embryos or (B, C) embryos injected with 
increasing amounts of Tbx5 RNA as indicated.  Arrows denote the location of the heart.  (D-
G) Whole-mount in situ hybridization showing expression of (D, E) Nkx2.5 and (F, G) 
myosin light chain (MLC) in (D, F) uninjected stage 37 embryos and (E, G) stage-matched 
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embryos injected with 1 ng of Tbx5 RNA.  (H) Tbx5 mis-expression leads to an increase in 
the cardiac mitotic index in control and Tbx5-injected embryos at stage 37.  Mitotic index 
was calculated as the percentage of cardiac cells labeled with pH3.  The data represents the 
mean of at least 3 different embryos.  Error bars denote the standard deviation and * denotes 
a statistically significant difference between Tbx5 injected and control embryos (at p < 0.05).  
(I)  Mitotic index for sections of the neural tube corresponding to the same position as the 
heart along the anterior-posterior axis.  The data represents the mean mitotic index of 4 
different embryos per condition, with 4 sections analyzed per embryo.  Error bars denote the 
standard deviation. (J)  Tbx5 mis-expression leads to an alteration in the timing and order of 
the cardiac differentiation program. RT-PCR analysis of the expression of Nkx2.5 as well as 
heart-specific isoforms of MHC, troponin, and tropomyosin, and skeletal muscle specific 
genes, MyoD and muscle actin, throughout early and mid-gestation stages of development in 
control (‘C’) or Tbx5 injected (‘T’) stage-matched embryos. All samples are derived from a 
single batch of eggs and identical results were achieved in at least two independent sets of 
experiments for each marker. EF1-alpha was used as a control for all RT-PCR reactions. 
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Figure 4.7. Model for potential mechanisms by which TBX5 functions to control embryonic
cardiac cell cycle progression.
Schematic of embryonic cardiac cell cycle shown in left hand panel and potential roles for
TBX5 in regulating G1/S progression. (1) TBX5 may function to induce the expression of a
growth factor, for example EGF or FGF required for cell cycle G1 progression. (2) TBX5 
may function to regulate E2F activity by controlling the phosphorylation state of pRB. (3) 
TBX5 could also negatively regulate general cell cycle inhibitors such as p27Xic. (4) 
Alternatively TBX5 may function to regulate the expression of a key component of the CDK-
cyclin complexes required for G1/S progression.
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CHAPTER 5 
SHP-2 is Required for the Maintenance of Proliferating 
Cardiac Progenitor Cells 
 
PREFACE TO CHAPTER 5
Chapter 5 deals with the requirement for the protein tyrosine phosphatase SHP-2
during heart development. SHP-2 functions to potentiate signaling downstream of receptor
tyrosine kinases such as FGF (Qu, 2000). Previous studies have suggested that SHP-2
functions during heart development, as several mutations to SHP-2 that cause it to become
constitutively active have been associated with the congenital heart disorder Noonan
Syndrome (Tartaglia et al., 2001). However, the requirements for SHP-2 during heart
development have not been addressed, as mouse embryos null for SHP-2 and Xenopus
embryos in which a dominant negative form of SHP-2 is expressed arrest at gastrula stages
(Tang et al., 1995; Yang et al., 2006). Here, we make use of a specific inhibitor of SHP-2,
NSC-87877. By treating heart field explants excised from embryos prior to the onset of
cardiac differentiation with this inhibitor, we bypass earlier requirements for SHP-2 in
mesoderm formation, and study the requirement for SHP-2 in heart development.
These experiments were performed in collaboration with Yvette Langdon, Anna
Berg, and Jackie Swanik. For this work, I developed and tested the heart field explant assay
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(based on Raffin et al., 2000), performed the FGF inhibitor experiments and mitotic index
studies, and assisted with the SHP-2 inhibitor and cell cycle inhibitor studies.
SUMMARY
The isolation and culturing of cardiac progenitor cells has demonstrated that growth 
factor signaling is required to maintain cardiac cell survival and proliferation.  In this 
study, we demonstrate that SHP-2 activity is required for the maintenance of cardiac 
precursors in vivo. In the absence of SHP-2 signaling, cardiac progenitor cells down-
regulate genes associated with early heart development and fail to initiate cardiac 
differentiation. We further show that this requirement for SHP-2 is restricted to 
cardiac precursor cells undergoing active proliferation. By demonstrating that SHP-2 is 
phosphorylated on Y542/Y580 and that it binds to FRS-2, we place SHP-2 in the FGF 
pathway during early embryonic heart development. Furthermore, we demonstrate 
that inhibition of FGF signaling mimics the cellular and biochemical effects of SHP-2 
inhibition and that these effects can be rescued by constitutive active/Noonan syndrome 
associated forms of SHP-2. Collectively, these results show that SHP-2 functions within 
the FGF/MAPK pathway to maintain survival of proliferating populations of cardiac 
progenitor cells and further suggest that the FGF/SHP-2/MAPK pathway may 
represent a general pathway required to maintain proliferating progenitor populations.  
 
INTRODUCTION
Cells of the cardiac lineage are amongst the first mesodermal cells to be allocated to a 
specific tissue type in vertebrates. By the onset of gastrulation, the cells which will give rise 
to cardiac tissue are located in two regions at the anterior edge of the mesoderm.  Extirpation, 
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explantation, and tissue isolation studies in amphibian and avian embryos are all consistent 
with the cells of the cardiac lineage being specified and committed to the heart lineage during 
these early stages of development (Dehaan, 1963; Sater and Jacobson, 1989; Warkman and 
Krieg, 2006). Once cells are committed to the cardiac lineage, the cells migrate laterally and 
anteriorly, and subsequently fuse at the ventral anterior midline to form the bilaminar heart 
tube comprised of an outer myocardial and an inner endocardial layer (van den Hoff et al., 
2004). It is during this period that the vertebrate heart expresses the first molecular markers 
of cardiac development Tbx5, Gata4, Tbx20 and Nkx2.5, the homologue of the Drosophila 
gene tinman (Fishman and Chien, 1997; Harvey et al., 2002). It is also during this time that 
the cardiac precursors begin a period of rapid proliferation (Pasumarthi and Field, 2002).  
The isolation and culturing of cardiac progenitor cells has strongly implied the 
requirement for growth factor function to maintain cardiac cell survival. Collectively these 
studies have shown that survival and proliferation of cardiac progenitor populations requires 
either the aggregation of clonal colonies, that the cells be co-cultured with heart tissue, or that 
the cultures be supplemented with a mixture of growth factors and cytokines (Kattman et al., 
2006; Kouskoff et al., 2005; Moretti et al., 2006; Parmacek and Epstein, 2005; Srivastava, 
2006; Wu et al., 2006). However the precise nature of the endogenous growth factors and the 
downstream signaling pathways required for survival or proliferation remain unidentified.  
SHP-2, also known as SH-PTP2, Ptpn11, PTP1D, or PTP2C, is the vertebrate 
homologue of the Drosophila gene corkscrew (Csw), a widely expressed non-receptor protein 
tyrosine phosphatase (PTP) known to function genetically and biochemically downstream of 
a number of growth factors including epidermal growth factors (EGFs), platelet derived 
growth factor (PDGF) and fibroblast growth factors (FGFs) (Feng, 1999; Pawson, 1994; Qu, 
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2000; Van Vactor et al., 1998; Zhang et al., 2000). The sequence, expression pattern and 
function of SHP-2 are highly conserved throughout evolution with genetic studies in a 
number of animal models all suggestive of a critical role for SHP-2 in early development. For 
example, mice homozygous for a null mutation in Shp-2 die at implantation, due to a failure 
in the development of the extra-embryonic trophectodermal lineage, while introduction of a 
dominant negative form of SHP-2 in Xenopus can completely block mesoderm formation in 
response to the FGF/MAPK pathway and leads to gastrulation arrest (Tang et al., 1995; Yang 
et al., 2006). Studies have also suggested a role for SHP-2 in heart development. Noonan 
syndrome, a relatively common autosomal dominant disorder that leads to a number of 
cardiac abnormalities including atrial septal defects, ventricular septal defects, pulmonary 
stenosus and hypertrophic cardiomyopathy, is associated with mutations in Shp-2 in 
approximately half of affected individuals (Noonan and O'Connor, 1996; Tartaglia et al., 
2001). All SHP-2 associated Noonan syndrome mutations are mis-sense mutations and occur 
within one of the two SRC-homology 2 (SH2) domains, a region required for protein-protein 
interactions, or within the phosphatase domain.  These mutations are thought to be involved 
in switching SHP-2 between its inactive and active states, and to act in a constitutive active 
fashion (Allanson, 2002; Digilio et al., 2002; Ion et al., 2002; Legius et al., 2002; 
Maheshwari et al., 2002; Schollen et al., 2003; Tartaglia et al., 2002; Tartaglia et al., 2001). 
However, the precise requirement for Shp-2 in heart development remains to be established.  
 In this study, we have bypassed the early embryonic requirements for SHP-2 by 
means of a cardiac explant assay. Using this assay, we define, a requirement for SHP-2 in 
maintaining cardiac precursor populations in vivo. In the absence of SHP-2 signaling all 
early cardiac makers are down regulated and cardiac cells fail to initiate cardiac 
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differentiation. We further show that SHP-2 is required for cardiac progenitor populations 
that are actively proliferating but not those that have exited the cell cycle. We show that 
SHP-2 functions directly downstream of FGF in this process; we show that inhibiting FGF 
gives the same phenotype as SHP-2 inhibition, that SHP-2 is directly phosphorylated on 
specific residues in vivo in response to FGF signaling, that SHP-2 co-immunoprecipitates 
with FRS, a component of the FGF pathway, and most critically that we can rescue the 
cardiac lineage and the downstream signaling pathways in FGF inhibited tissues by the 
expression of a constitutive active/Noonan syndrome version of SHP-2, implying that the 
FGF/SHP-2 pathway is a general pathway in development that functions to maintain 
progenitor cell populations.  
 
RESULTS
SHP-2 is required for MHC expression in cardiac tissue  
To begin to elucidate the molecular pathways involved in cardiac cell survival, we have 
focused on the role of SHP-2 during the early stages of heart development. Clinical studies in 
humans and genetic studies in mice are all consistent with a role for SHP-2 in early heart 
development. However it remains unclear if SHP-2 acts directly or indirectly in the cardiac 
lineage. Western blot analysis with an antibody specific for total SHP-2 shows SHP-2 to be 
present throughout stages of early Xenopus embryogenesis, and in embryonic heart tissue 
(Figure S1A-B). 
Having established that SHP-2 is expressed in early embryos, we next tested the 
requirement for SHP-2 in early heart development. To bypass the early embryonic 
requirement for SHP-2, we have used a cardiac explant assay. Based on anatomical and gene 
136
expression studies in Xenopus, at late neurulation (stage 22) the cardiac precursors exist in 
two cell populations which lie directly posterior to the cement gland along the anterior-
ventral aspects of the embryo (Dale and Slack, 1987; Moody, 1987; Raffin et al., 2000; Sater 
and Jacobson, 1989). When dissected and cultured in isolation this tissue forms a beating 
heart while the donor embryo completely lacks any cardiac tissue (Xenopus can develop to 
late tadpole stage in the absence of a functioning heart or circulation). We have carried out an 
extensive analysis of these explants using early, mid and late molecular markers of heart 
tissue and show that the explants display a temporal and spatial expression of cardiac genes 
that faithfully recapitulates that of control (unmanipulated) embryos (Figure 1A-B). 
However, if explants are treated with a specific SHP-2 inhibitor NSC-87877 (Chen et al., 
2006), the cardiac marker myosin heavy chain (MHC) is dramatically down-regulated 
(Figure 1C). Previous studies have shown that NSC-87877 can also inhibit SHP-1, however 
since SHP-1 is not expressed during the earlier stages of embryogenesis the defects we 
observe are most likely due to the inhibition of SHP-2. To confirm the specificity of NSC-
87877, we show that its effect on MHC can be rescued by injection of the Noonan syndrome-
associated constitutively active form of human SHP-2, N308D (Shp-2 N308D) but not a 
phosphatase dead version of N308D (Figure 1C; data not shown). Together, these data 
indicate that SHP-2 signaling is required to induce or maintain expression of MHC.  
 
SHP-2 signaling is required for the maintenance of cardiac progenitors 
Since we observed that the SHP-2 is required for MHC expression in cardiac tissue, we 
addressed whether this effect is specific for MHC or reflects a general requirement for SHP-2 
signaling in heart development. To establish the role of SHP-2 in heart development and to 
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determine how rapidly SHP-2 inhibition effects cardiac gene expression, we assayed cardiac 
explants for expression of Nkx2.5, Tbx5, Tbx20 and the cardiac differentiation marker 
MLC1v at time points corresponding to stage 22, the stage when the cardiac precursors are
two distinct lateral populations of cells; stage 26, the period when the two cardiac precursors
populations are positioned at the anterior, ventral region of embryo flanking the midline;
stage 29 when the cardiac fields fuse across the ventral midline and stage 33 when the
bilaminar heart tube initiates cardiac looping. These studies show that there is a progressive 
loss of all three early markers with increasing length of SHP-2 inhibition. We observe that 
controls and treated tissue are indistinguishable at stage 22 (Figure 2A-C) however by early 
tailbud stage (St. 26) cardiac precursors in treated explants remain in two bilateral 
populations while the cardiac precursors in controls have migrated toward the midline 
(Figure 2A-C). At stage 29, when the hearts in control explants have formed a linear heart 
tube, the cardiac fields in SHP-2 inhibited explants remain unfused and display reduced 
expression of Nkx2.5, Tbx5, and Tbx20. Similarly, at stage 33, Nkx2.5, Tbx5, and Tbx20 
expression appears to continue to be restricted to a subset of tissue at the leading edge of the 
cardiac field or is absent entirely. The expression of the cardiac differentiation marker 
MLC1v’ is never initiated in SHP-2 inhibited explants (Figure 2D).  Overall there appears to 
be a progressive and rapid loss of early cardiac marker expression in SHP-2 inhibited 
explants and markers of cardiac differentiation fail to be expressed (Figure 2A-D). We do 
note however, that cardiac cells at the leading edge continue to express Tbx5 until at least 
stage 33 (Figure 2B, arrows).  
To confirm and extend these findings we tested explants for expression of the early 
cardiac/endoderm markers Gata4, Gata5, and Gata6. Similar to Nkx2.5, Tbx5, and Tbx20, we 
detect a dramatic down-regulation of Gata4, Gata5 and Gata6 (Figure S2).  Moreover, we 
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have found that expression of the early cardiac markers Nkx2.5 and Tbx5 can be restored in 
SHP-2 inhibited explants by constitutively active SHP-2 N308D (Figure 1C, 2E, data not 
shown). Thus the effects of SHP-2 inhibition on the expression of both early and late heart 
markers can be rescued by restoring SHP-2 activity. Collectively, these results suggest that 
SHP-2 is required to maintain the expression of early cardiac markers in most of the cardiac 
field and for the onset of cardiac differentiation.  
 
SHP-2 signaling is required for pharyngeal mesoderm but is not required for the 
induction and/or maintenance of endodermal or endothelial tissue types 
To determine whether the requirements for SHP-2 are cardiac-specific, we assayed the 
effects of SHP-2 inhibition on the additional cell types present in tissue explants; endoderm, 
endothelial cells, and overlying pharyngeal mesoderm (Figure 3A). Similar to our findings 
with cardiac-specific markers, SHP-2 signaling is required for the maintenance of the 
pharyngeal mesoderm-associated genes Fgf8, Tbx1, and Isl1 as inhibition of SHP-2 signaling 
results in loss of expression of these genes in explanted tissue (Figure3B and data not 
shown). In contrast, results show that SHP-2 signaling is not required for the expression of 
genes associated with the deep endoderm (Edd and Endocut positive tissue), or pharyngeal 
endoderm (Sox2 positive) (Figure 3C). Similarly, we observe that SHP-2 signaling is not 
required for the expression of the endothelial cell markers Xmsr and Ami (Figure 3C). We do 
note however, that Xmsr and Ami are expressed in SHP-2 inhibited tissue in coherent un-
branched patterns verses control explants. Collectively, these results show SHP-2 is required 
for the maintenance of early markers of cardiac and pharyngeal mesoderm but is not required 
for endodermal or endothelial cell types.  
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Inhibition of SHP-2 Results in a Progressive Increase in Cell Death 
To determine if the loss of cardiac tissue in response to SHP-2 inhibition is due to defects in 
cardiac cell survival or proliferation, we examined programmed cell death in control explants 
and explants in which SHP-2 signaling was inhibited. Explants were treated with the SHP-2 
inhibitor beginning at stage 22, and analyzed at stages 22, 26, 29, and 33. TUNEL staining of 
cardiac explants reveals that at stage 22 there is no apparent difference in cardiac cell death 
in the ridge of mesodermal tissue which contains the cardiac tissue in either control or SHP-2 
inhibited explants (Fig. 4A) however, by stage 26 we begin to detect an increase in TUNEL 
positive cells in SHP-2 inhibited explants along the cardiac ridge (Fig. 4A). By stages 29 and 
33, the number of apoptotic cells in the SHP-2 inhibited explants has further expanded in the 
cardiac ridge (Fig. 4A). Therefore, in the absence of SHP-2 signaling, cardiac cells cease 
development and undergo programmed cell death initiated by stage 26.  
Since studies have implied a role for SHP-2 in cell cycle progression (Guillemot et 
al., 2000; Yuan et al., 2003; Yuan et al., 2005), we tested if withdrawal from the cell cycle 
could account for the observed loss of cardiac marker expression and programmed cell death 
in SHP-2 inhibited explants. Therefore, we treated explants with cell cycle inhibitors and 
determined the effects on the expression of early and late heart markers. As expected, the 
culture of explants in media containing aphidicolin (Aph) leads to a dramatic reduction in the 
number of mitotic cells (Figure 4B).  Results show that arrest of tissue at the G1/S phase by 
the addition of Aph leads to a loss of the early cardiac markers Nkx2.5, Tbx5, Tbx20, and 
Gata6 (Figure 4D,E). Gata4 and Gata5 are still expressed in Aph-treated explants, though 
reduced in expression (Figure 4E).  In contrast to SHP-2 inhibition, G1/S interphase arrest by 
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Aph has no effect on the expression of the expression of markers of cardiac differentiation 
including Hsp27, MLC1v’, MHC, and tropomyosin (Figure 4E,F). However, as predicted, we 
observed a reduction in the size of the hearts in the Aph-treated explants. These results are 
not due to treatment with Aph per se since identical results were obtained with M phase 
arrest by treatment with colchicine (Figure 4G). Thus, these results suggest that the lack of 
cardiac differentiation in SHP-2 inhibited tissue is not the result of cell cycle arrest and 
further implies that cell cycle arrest and cardiac differentiation are independently regulated in 
vivo. 
SHP-2 is preferentially required in proliferating cardiomyocytes 
At the early stages of heart development, when cardiac explants are removed, the majority of 
cardiac cells are proliferating. However as cardiac differentiation is initiated, cells 
progressively begin to exit the cell cycle, and a smaller proportion of cardiac cells continue to 
cycle (Goetz et al., 2006). To determine if SHP-2 is required for the maintenance of 
proliferating cardiomyocytes, SHP-2 signaling was blocked in cardiac explants at a series of 
developmental stages: late neurula (St. 22 and 24), early tailbud (St. 26), and late tailbud (St. 
29); and cultured to tadpole stage (St. 37) (Fig. 5A). Results from these studies show that 
SHP-2 signaling is required during a specific developmental period for MHC expression; 
treatment at stage 22 shows no MHC expression, stages 24 and 26 show a marked reduction 
in MHC expression, while treatment from stage 29 results in hearts with high levels of MHC 
expression, but that are reduced in size (Fig. 5A). Our results demonstrate that SHP-2 
signaling is required during late neurula stages for the expression of MHC in cardiac tissue 
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with SHP-2 signaling becoming less critical at a time point when increasing numbers of 
cardiac cells begin to exit the cell cycle (Fig. 5B).  
To determine if SHP-2 signaling is required for the maintenance of proliferating 
cardiac cells, we inhibited SHP-2 signaling beginning at stage 29, a period when the heart 
consists of both dividing cardiomyocytes as well as cardiomyocytes that have exited the cell 
cycle (Goetz et al., 2006). By stage 37, SHP-2 inhibited explants have a mitotic index that is 
approximately half that of control explants (Fig. 5C,D), suggesting a requirement for SHP-2 
in the maintenance of proliferating cardiac cells. Collectively this data suggests that SHP-2 
signaling is preferentially required for the maintenance and survival of proliferating cardiac 
cells.  
 
SHP-2 functions downstream of FGF pathway to regulate cardiac survival 
The phosphorylation state of SHP-2 has been demonstrated to be reflective of its function 
within a specific RTK pathway (e.g. (Bjorbaek et al., 2001)). For example, SHP-2 has been 
shown to be phosphorylated on tyrosine residues 542 and 580 in response to FGF or PDGF 
stimulation but not EGF stimulation (Araki et al., 2004). To determine the phosphorylation 
state of SHP-2 in heart tissue we immunpoprecipitated SHP-2 from embryonic and adult 
hearts and conducted western blots with a SHP2-phospho-Y542 antibody. Results show that 
SHP-2 is phosphorylated at residue Y542 in cardiac tissue during the period when SHP-2 
functions to maintain cardiac cell survival (Figure 6B). Consistent with these results, 
immunohistochemistry shows that both phospho-Y542 SHP-2 and phospho-Y580 SHP-2 are 
expressed in the developing myocardium (Figure 6A). Collectively these results demonstrate 
that phosphorylation of SHP-2 is tissue specific and SHP-2 is present in its phosphorylated 
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state in developing myocardial tissue, and therefore most likely acting within the FGF and/ or 
PDGF pathways. 
In tissue culture SHP-2 directly interacts with the docking protein FRS upon FGF but 
not PDGF stimulation. To test if SHP-2 is functioning downstream of FGF in embryonic 
heart tissue in vivo, we carried out co-immunoprecipitation experiments from isolated 
embryonic heart tissue. Results show that in isolated embryonic heart tissue SHP-2 directly 
interacts with FRS (Figure 6B). This is the first demonstration that SHP-2 interacts with FRS 
in vivo.
Since the decrease in Nkx2.5 expression in SHP-2-inhibited explants is similar to that 
reported in embryos which genetically lack Fgf8 (Reiter et al., 1999) or those in which the 
endoderm adjacent to the cardiac mesoderm has been surgically removed (Alsan and 
Schultheiss, 2002), and since we observe phophorylation of SHP-2 on tyrosine residues 542 
and 580 and direct association of SHP-2 with FRS, we reasoned that FGF acts through SHP-
2 to maintain the cardiac lineage. To investigate this possibility, we tested the effects of 
inhibiting FGF signaling in cardiac explants. Results from these assays show that similar to 
SHP-2 inhibition, treatment of cardiac explants with the FGFR inhibitor SU5402 leads to a 
decrease in expression of early and late cardiac markers (Figure 7A). However, we note that 
in contrast to SHP-2 inhibition, FGF inhibition leads to a decrease of Tbx5 both in lateral 
tissue and at the leading edge of the cardiac ridge (Fig. 7A,B). To determine if the loss of 
cardiac gene expression temporally mimics that seen with SHP-2 inhibition, explants were 
treated with SU5402 at defined time points of cardiac development. As observed with SHP-2 
inhibition, the cardiac explants strongly respond to FGF inhibition between stages 22 and 26 
(data not shown) and western blots of cardiac explants lacking SHP-2 activity or FGF 
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signaling show a dramatic decrease in phospho-ERK (3 fold or more in response to inhibition 
as assayed by densitometry) (Figure 7C-D). Consistent with SHP-2 acting downstream of 
FGF, injection of a constitutive active SHP-2 (N308D) in FGFR inhibited explants rescues 
expression of the early heart markers Nkx2.5 and Tbx5. (Figure 7B and data not shown). 
Taken together these studies demonstrate that SHP-2 functions in the FGF pathway to 
regulate cardiac progenitor survival.  
 
Discussion
There has been great clinical interest in identifying cardiac progenitor cells from various 
sources however, little effort has been expended to understand the precise nature of the 
endogenous growth factor signaling pathways required for survival or proliferation of cardiac 
cells (Kattman et al., 2006; Kouskoff et al., 2005; Moretti et al., 2006; Parmacek and Epstein, 
2005; Srivastava, 2006; Wu et al., 2006). To date, studies of early cardiac tissue have implied 
a requirement for growth factors to maintain cardiac cell survival, with survival and 
proliferation of cardiac progenitor populations requiring either the aggregation of clonal 
colonies, that cardiac progenitors be co-cultured with heart tissue, or that the cultures be 
supplemented with a mixture of growth factors and cytokines. However, neither the 
endogenous growth factor nor the signaling cascade required for cardiac progenitor survival 
has been identified (Parmacek and Epstein, 2005; Srivastava, 2006). To address these issues, 
we have characterized the endogenous role for SHP-2, a non-receptor protein phosphatase 
disrupted in the congenital heart disease Noonan syndrome, and have demonstrated that 
SHP-2 functions in the FGF pathway to maintain the survival of proliferating cardiomyocytes 
in vivo.
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SHP-2 and cardiac cell cycle 
The time at which SHP-2 is required for the maintenance of cardiac progenitor cells 
corresponds with a period of rapid cardiac proliferation (Fishman and Chien, 1997; Goetz et 
al., 2006; Pasumarthi and Field, 2002).  In many tissues, such as muscle and the nervous 
system, the withdrawal of cells from the cell cycle is tightly associated with the onset of 
terminal differentiation (Alexiades and Cepko, 1996; Dyer and Cepko, 2001; Lathrop et al., 
1985; Li and Vaessin, 2000; Walsh and Perlman, 1997). In contrast, relatively little is known 
about the relationship between the cell cycle progression and terminal differentiation in the 
heart.  
Our previous work has demonstrated cardiac cells that initiate terminal differentiation 
retain the ability to divide (Goetz et al., 2006).  In the current study, we have extended these 
findings to demonstrate that while cardiomyocytes of the adult frog ultimately exit the cell 
cycle, cells expressing markers of terminal differentiation are still undergoing cell division 
(as shown by pH3) at stage 42.  By this stage, cardiac morphogenesis is largely complete and 
all cardiac cells, including those still dividing, possess the anatomical and molecular 
hallmarks of differentiation suggesting that, at least in the heart, the onset of terminal 
differentiation does not require cell cycle exit.  Our findings are broadly consistent with 
recent work showing that cell cycle exit and terminal differentiation are mechanistically 
separable processes (Grossel and Hinds, 2006; Nguyen et al., 2006; Vernon and Philpott, 
2003) .  As a corollary to these experiments, we have also examined here the consequences 
of induced cell cycle arrest on cardiac differentiation and found that blocking the cell cycle in 
S phase with aphidicolin, or in M phase with colchicine does not result in a block in cardiac 
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differentiation.  Interestingly, however, we have found that cell cycle arrest results in reduced 
expression of the early cardiac markers Tbx5, Tbx20, and Nkx2.5. Thus, these findings are 
consistent with the observation that none of these early cardiac proteins are required for 
cardiac differentiation, and further imply that the expression of these early cardiac 
transcription factors may be cell cycle-dependent.  
Coinciding with program cell death, we also observe that blocking SHP-2 signaling 
leads to a failure of early cardiac cells to fuse at the ventral midline. At present we can not 
distinguish between a role for SHP-2 as a trophic factor and/or a role for SHP-2 in cell 
adhesion. However, genetic studies in zebrafish and mouse strongly imply that the inability 
of the cardiac fields to fuse is not the primary cause of the donwregulation of early cardiac 
markers or the failure of SHP-2 inhibited explants to initiate cardiac differentiation. For 
example, genetic mutations resulting in cardiac bifidia, such as Gata5, hand2, Casanova, and 
Bonnie and clyde and miles apart in zebrafish (Alexander et al., 1999; Kupperman et al., 
2000; Reiter et al., 1999) or Gata4 and MesP1 (Molkentin et al., 1997; Saga et al., 1999) in 
mouse, as well as genetic mutations in cardiac cell adhesion proteins (Trinh and Stainier, 
2004), show no alteration in the expression of early cardiac markers such as Nkx2.5 or of
markers associated with terminal differentiation. Therefore, it is most likely that the failure of 
cardiac cells to migrate is a secondary consequence of cell survival or it maybe that SHP-2 
has two temporally distinct roles in heart development one, regulating cell adhesion and a 
second in cell survival.  
 
SHP-2 and the FGF pathway 
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In this study we show SHP-2 to be phosphorylated on tyrosines 542 and 580 in the 
embryonic heart and that it co-immunoprecipitates with FRS-2, demonstrating an in vivo 
interaction between SHP-2 and FRS-2 for the first time.  Moreover, given that we have 
shown inhibitors of both SHP-2 and FGFR to cause comparable cardiac phenotypes, and that 
a constitutive active form of SHP-2 can rescue formation of cardiac tissue in FGF inhibited 
explants, we conclude that SHP-2 participates in the FGF signal transduction pathway in 
Xenopus embryonic hearts.  
Recent work examining the role of FGFs in response to cardiac damage or injury 
lends further support for the direct role of SHP-2 in cardiac cell survival.  The over-
expression of both FGF-1 and FGF-2 have been shown to promote the survival of adult 
cardiomyocytes in response to ischemic injury in vivo (House et al., 2005; Jiang et al., 2002; 
Jiang et al., 2004; Palmen et al., 2004) and the cardioprotective effects of FGF-2 in the adult 
myocardium are mediated through the MAPK pathway (House et al., 2005); the same branch 
of the FGFR signaling cascade which we have shown in cardiac tissue functions through 
SHP-2.  Interestingly, the specific function of FGF-2 in preventing programmed cell death in 
response to ischemic insult was shown to be independent of its mitogenic or angiogenic 
functions, suggesting that FGF-2 is functioning specifically to promote cardiomyocyte cell 
survival (Jiang et al., 2004). Together with our data showing that SHP-2 activity downstream 
of FGFR is required for the maintenance of proliferating cardiac progenitor cells, these data 
suggest that the FGF/MAPK pathway functions in promoting cardiac progenitor cell survival 
during development and further suggests that the FGF/SHP-2/MAPK pathway must be 
maintained to promote survival of cardiac progenitor cells in vitro. Intriguingly, the 
FGF/SHP-2 has also recently been shown to be required for the survival of trophectoderm 
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stem cells and for the ability of hematopoitetic stem cells to self-renew (Chan et al., 2006; 
Yang et al., 2006) thus, raising the possibility that the FGF/SHP-2 pathway is a common 
pathway for cell progenitor survival.  
 
Experimental Procedures
DNA Constructs 
SHP-2 N308D and N308D-PTP were generated by site-directed mutagenesis (Stratagene) 
according to the manufacturer’s protocol. Primer sequences available upon request. For 
epitope labeling, each construct was subcloned into a HA modified pcDNA3.1(+) vector 
kindly provided by Da-Zhi Wang. 
 
Embryo Injections 
Xenopus embryos were obtained by in vitro fertilization (Smith and Slack, 1983), cultured in 
0.1X Modified Barth’s Saline (MBS) and staged according to the Normal Table of Xenopus 
laevis (Nieuwkoop and Faber, 1975). RNA for injection was synthesized using the 
mMessage in vitro transcription kit (Ambion) according to the manufacturer’s instructions.  
Embryos were injected at the one-cell stage with 2ng RNA dissolved in 10nl water. 
 
Cardiac Explants 
Tissue posterior to the cement gland and including the heart field was excised at stage 22 in a 
manner similar to that described by Raffin et al. (Raffin et al., 2000). The explants include 
overlying pharyngeal endoderm and some foregut endoderm. Explants were cultured at 23°C
in either 2.5mM DMSO, 500µM NSC-87877 (Sigma), 50µM SU5402 (Pfizer), 150µM
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aphidicolin (Sigma), 20mM hydroxyurea (Sigma), or 50µM colchicine (Sigma) in 1X MBS 
(Chemicon) (Chen et al., 2006; Dasso and Newport, 1990; Harris and Hartenstein, 1991; 
Mason et al., 2002).  Explants were cultured until specified stages and fixed for 2 hours in 
MEMFA at room temperature. 
 
Immunoblotting 
To detect endogenous SHP-2, five embryos per condition were homogenized in lysis buffer 
(100 mM NaCl, 20 mM NaF, 50 mM Tris pH 7.5, 10 mM Sodium Pyrophosphate, 5 mM 
EDTA, 1% NP40 and 1% Sodium Deoxycholate) with the addition of complete protease 
inhibitor cocktail (Roche) and PMSF (Sigma) and processed according to standard protocols. 
In vitro translation of SHP-2 was performed using wheatgerm TNT coupled
transcription/translation (Promega) according to manufacturer’s instructions.
Western blots were probed with anti-mouse total SHP-2 antibody PTP1D/SHP-2 (BD 
Transductions Laboratories) at 1:2500. Heart explant western blots were probed with 
antibodies against phospho-ERK1/2 and total ERK1/2, with each antibody used at 1:1000 
(Cell Signaling). Whole heart immunoblots were prepared from seventy dissected hearts as 
described above and probed with antibodies against total SHP-2.  Calf intestinal phosphatase 
(CIP) treatment was carried out by incubating whole embryo lysate or heart lysate with 5U of 
CIP, CIP buffer, EDTA-free Complete protease inhibitors at 37°C for 1.5 hr prior to western 
blot analysis.  Loading levels of tissue were standardized in pilot runs of western blots 
assayed by densitometry. 
 
Whole Mount Antibody Staining and in situ hybridization: 
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Whole-mount antibody staining of whole embryos and explants were performed as described 
(Kolker et al., 2000) with anti-tropomyosin (1:50; Developmental Studies Hybridoma Bank),
anti-Myosin Heavy Chain (MHC) (1:500 Abcam), and phospho-histone H3 (1:200 Upstate)
to mark cells in M phase (Goetz et al., 2006) and visualized on a Leica MZFLIII microscope.
Immunostaining of histological sections was performed according to protocols and 
procedures described previously (Goetz et al., 2006). For these studies, phospho-SHP-2 
(Tyr542) (Cell Signaling) and phospho-SHP-2 (Tyr580) (Cell Signaling) were both used at 
1:1000 to mark phosphorylated SHP-2 in the heart. Whole-mount in situ hybridizations were
performed with Nkx2.5 (Tonissen et al., 1994), Tbx5 (Brown et al., 2003; Horb and Thomsen,
1999), Tbx20 (Brown et al., 2003), Gata4 (Jiang and Evans, 1996), Gata5 (Jiang and Evans,
1996), Gata6 (Gove et al., 1997), MLC1v’ (IMAGE clone 4408657, GenBank Accession 
No.: BG884964) ), Sox2 (Lu et al., 2004), Endocut (Costa et al., 2003), Ami (Inui and
Asashima, 2006), Xmsr (Xenopus EST clone XL327k24ex (Mills et al., 1999)), using
protocols as previously described (Harland, 1991). Embryos were cleared using 2:1 benzyl
benzoate/benzyl alcohol.
Whole Mount TUNEL Staining 
Apoptotic cells were detected by TUNEL staining as previously described (Hensey and
Gautier, 1998). The chromogenic detection of DIG-dUTP incorporation was carried out with
BCIP (175ug/mL, Roche), and nitro blue tetrazolium (337 ug/mL, Roche) substrates.
Immunoprecipitation
Embryos were injected, as described above, with 2ng of HA-tagged full length SHP-2 RNA. 
1300 hearts were dissected at stage 35 and homogenized in lysis buffer (50 mM Tris 7.6, 150 
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mM NaCl, 10 mM EDTA, 1 % Surfact-Amps Triton-100, 25 mM PMSF supplemented with 
1 Complete protease inhibitor mini tablet (Roche). Supernants were precleared with protein 
A/G beads for two hours at 4°C.  20 µl of HA beads (Covance) or 30 µl of Shp-2 agarose 
beads (Santa Cruz Biotechnology) was added to the supernant and rotated overnight at 4°C.  
Immunoblotting was performed using anti-HA (Covance) at 1:1000, anti-FRS-2 (Santa Cruz) 
at 1:200, anti-Shp-2 (BD Transduction Labs at 1:2500, and anti-phospho Y-580 Shp-2 (Cell 
Signaling) at 1:1000.   
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Figure 5.1. Inhibition of SHP-2 activity results in loss of MHC expression.
Tissue explants show identical cardiac expression profiles as intact embryos. (A) Whole 
mount antibody staining of cardiac differentiation with tropomyosin (Tmy; red) or myosin 
heavy chain (MHC; red) antibodies as indicated, in whole embryos and cardiac explants at 
stages 22 (neurula), 29 (tailbud), and 37 (tadpole). (Scale bar = 0.5 mm).(B) Whole mount in 
situ hybridization for early heart markers Tbx5, Tbx20, Nkx2.5 in whole embryos and cardiac 
explants at stage 22, 29 and 37, as indicated (Scale bars = 1 mm). 
(C) MHC expression is dependent on SHP-2 activity. Whole mount antibody staining for 
MHC (red) in cardiac explants taken from uninjected (Control) embryos or embryos injected 
with Shp-2 N308D and treated with either buffer or DMSO carrier as controls or with NSC-
87877  as indicated.  BF= bright field. (Scale bars = 0.5 mm). 
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Figure 5.2. SHP-2 activity is required for the maintenance of cardiac markers
(A-D) Cardiac explants were isolated and cultured in DMSO or NSC-87877 beginning at 
stage 22. In situ hybridization was performed on explants with Nkx2.5 (A), Tbx5 (B), Tbx20 
(C), and MLC1v (D) at stages 22, 26, 29, and 33, as indicated. (Scale bars = 1 mm). 
 (E) In situ hybridization of Nkx2.5 in uninjected (control) or Shp-2 N308D injected explants 
treated with DMSO or NSC-87877. (Scale bar = 1mm). 
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Figure 5.3. SHP-2 signaling is required for pharyngeal mesoderm
(A) Schematic of tissues and rudimentary organ structures contained in the explants.  (B) 
Cardiac explants were isolated and cultured in DMSO or NSC-87877 beginning at stage 22. 
In situ hybridization was performed on explants with Tbx1 or Fgf8, at stages 22, 26, 29, and 
33. (Scale bar = 1 mm).  (C) Whole mount in situ hybridization of endocut, endodermin,
Sox2, Ami, and Xmsr in stage 37 whole embryos and cardiac explants treated with DMSO or 
NSC-87877, as indicated (Scale bar = 1 mm). 
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Figure 5.4. Blocking the cardiac cell cycle results in loss of early, but not late, cardiac
markers.
(A) TUNEL staining of control cardiac explants (DMSO) and explants treated with NSC-
87877.  Cell death examined in explants at stages 22, 26, 29, and 33, as indicated.  Red 
arrows denote cardiac cells, yellow arrows denote endodermal cells (Scale bar = 1 mm). (B) 
Cardiac explants isolated and cultured in DMSO or Aphidicolin (Aph) beginning at stage 22 
and fixed at stage 37. Whole mount immunostaining of explants with phospho-histone H3 
specific antibody (pH3; red).  (Scale bars = 1mm). In situ hybridization on explants with 
early the cardiac markers (C) Tbx5, Tbx20, Nkx2.5, (D) Gata4, Gata5, and Gata6. (Scale bar 
= 1 mm); (E) with the cardiac differentiation markers Hsp27 and MLC1v’ and (F) by whole 
mount immunostaining with the cardiac differentiation markers Tmy and MHC. (BF- bright 
field, scale bar = 1 mm).(G) Explants were treated with DMSO or colchicine (Colch) to 
block cells in M phase of the cell cycle.  In situ hybridization was performed to examine 
expression of Tbx5, Nkx2.5, and MLC1V’, as indicated.  (Scale bar = 1mm)
157
Figure 5.5. SHP-2 is required for the survival of proliferating cardiac cells.
(A) Cardiac explants were treated with the SHP-2 inhibitor NSC-87877 beginning at stage 
22, 24, 26, or 29 as indicated, cultured to stage 37 and stained with an MHC antibody (red);  
BF= bright field. (Scale bars = 0.5 mm). (B) Representative transverse sections through stage 
33, 35, 42 and adult Xenopus hearts with antibodies against MHC (green) or Tmy (green), 
phospho histone H3 (pH3; red) and DAPI (blue) (Scale bar = 10 Om). (C) Representative 
transverse sections through the cardiac tissue of a DMSO-treated and an explant treated with 
NSC-87877 beginning at stage 29, and stained with antibodies against phospho-histone H3 
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(pH3, red), and Tmy (green), as assessed at stage 37 (Scale bar = 200 µm). (D) Cardiac 
mitotic index of explants treated beginning at stage 29 with DMSO (blue bar) or NSC-87877 
(magenta bar) and assessed at stage 37.  Bars represent the mean mitotic index of 4 explants 
per condition.  Error bars denote the standard deviation.  * denotes a statistically significant 
reduction in mitotic index of NSC-87877 treated explants (P = 0.0021).     
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Figure 5.6. Phosphorylated SHP-2 is expressed in early cardiac tissue.
(A) Transverse cryosections through the heart of control embryos stained with tropomyosin  
to mark cardiac tissue (Tmy; green), DAPI, to mark cell nuclei (blue), and  anti-total SHP-2, 
anti-phospho-542 SHP-2 or anti-phospho-580 SHP-2 (all shown in red). Arrows denote 
endocardial cells that are negative for SHP-2. (All samples from stage 37, scale bars = 100 
µm).(B)  SHP-2 interacts with FRS in vivo. Hearts from FL-HA-SHP-2 derived embryos 
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were dissected at stage 35 embryos and immunoprecipitated with an anti-SHP-2 antibody (+) 
or beads with no antibody (-).Western analysis was then performed using antibodies specific 
for SHP-2 total, phospho-542 SHP-2 and FRS-2. Note the level of SHP-2 phopho-542 in 
input was below levels of detection. 
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Figure 5.7. MAPK signaling through the FGF pathway in the heart requires SHP-2.
(A) Whole mount in situ hybridization for Tbx5, Tbx20, and Nkx2.5 and whole mount 
immunostaining for MHC (red) a marker of cardiac differentiation were performed on 
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explants treated with DMSO as a control, or the FGFR1 inhibitor SU5402 (Scale bars = 1 
mm).  (B) Explants isolated from uninjected (Control) or SHP-2 N308D injected embryos 
were cultured in DMSO or inhibitor (NSC-87877 or SU5402) and in situ hubridizations were 
performed for the early cardiac markers Nkx2.5 and Tbx5 (Scale bars = 1 mm).  (C-D) 
Western blot analysis of NSC-87877 (C) or SU5402 (D) treated explants for phosphorylated 
and total ERK expression, -tubulin is used as a loading control. 
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Figure 5.S1. SHP-2 is expressed in during early Xenopus development
(A) In vitro translation of Xenopus SHP-2 in the sense orientation or anti-sense orientation 
(Neg.) probed with an anti-SHP-2 antibody.  (B) Western blot analysis of SHP-2 expression 
during early embryogenesis using lysate from whole embryos at stages 10.5 (gastrula) 
through stage 40 (late tadpole). Anti-EF-2 was used as a loading control.  (C) Western blot 
analysis of SHP-2 and Tmy in whole embryos and isolated heart tissue from stage 37 
embryos. -Tubulin is the loading control. 
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Figure 5.S2. Gata 4, 5, and -6 expression is reduced in SHP-2 inhibited explants.
Cardiac explants were isolated and cultured in DMSO or NSC-87877 beginning at stage 22. 
In situ hybridization was performed on explants with Gata4, Gata5 and Gata6. (Scale bars = 
0.5mm). 
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CHAPTER 6 
Conclusions and Future Directions 
 
The tissue-specific regulation of cell proliferation plays a crucial role in 
organogenesis during development.  However, the mechanisms by which this is achieved are 
not yet well understood.  The work presented in this dissertation begins to address this 
problem in the developing heart by 1) examining the requirement for the transcription factor 
TBX5 in cardiac morphogenesis, and identifying a role for TBX5 in promoting cardiac cell 
cycle progression; and 2) characterizing the requirement for the protein tyrosine phosphatase 
SHP2 in the maintenance of proliferating cardiac progenitors during early cardiac 
development. 
 
Cardiac cell cycle progression and morphogenesis
In Chapters 2 and 3, I describe the morphological abnormalities that arise in the developing 
heart as the result of depletion of the T-box transcription factors TBX5 and TBX20.  We 
observed that in embryos lacking TBX5 or TBX20, the hearts are reduced in size and contain 
fewer cardiac cells.  However, early cardiac genes, as well as markers of cardiac 
differentiation are expressed normally, indicating that cardiac precursors are properly 
specified and able to undergo terminal differentiation in the absence of TBX5 or TBX20.  
We have provided the first evidence that TBX20 is required for vertebrate heart
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development, as well as showing that Xenopus embryos lacking TBX5 display a cardiac 
phenotype similar to that observed in the mouse (Bruneau et al., 2001), thus demonstrating 
that the function of TBX5 is conserved between vertebrates.  The precise cellular functions 
of TBX5 and TBX20 have not been defined, however.  Few direct transcriptional targets in 
the heart have been identified for either protein.  Those that have been identified include 
Atrial naturitic factor (ANF) in the case of TBX5 (Bruneau et al., 2001); and Tbx2 and 
possibly N-myc in the case of TBX20 (Cai et al., 2005).     
 The reduced number of cardiac cells that we observed both in hearts lacking TBX5 
and TBX20 led us to hypothesize that these proteins are required for cell proliferation within 
the heart.  A subsequent study of TBX20 performed in the mouse revealed that TBX20 
promotes proliferation within the chamber myocardium by repressing Tbx2 (Cai et al., 2005).  
TBX2 normally functions to inhibit cell cycle progression in the non-chamber myocardium 
by repressing N-Myc, a transcription factor that promotes cell proliferation within the heart.    
In addition to relieving repression of N-myc by TBX2, TBX20 has also been shown to 
activate transcription of N-myc in in vitro transcriptional assays, suggesting that N-myc may 
also be a target of TBX20.  Thus, TBX20 acts as  a positive regulator of cell cycle 
progression within the heart (Cai et al., 2005).  
We have tested this hypothesis with respect to TBX5 in Chapter 4.  Our detailed 
analysis of the defects resulting from depletion of TBX5 from Xenopus embryos has revealed 
that cardiac cells fail to progress through S phase of the cell cycle in the absence of TBX5.  
This suggests that, like TBX20, TBX5 promotes cardiac cell proliferation in the specific 
regions of the heart where it is expressed.  In this way, TBX5 is required to establish of 
proper cardiac morphology during development.  In addition, we have also shown that 
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depletion of TBX5 leads to a mis-regulation in the timing of cardiac differentiation, which is 
also likely to contribute to the cardiac abnormalities observed in these embryos.  
Mutations to Tbx5 in humans have been associated with the congenital heart disorder 
Holt-Oram Syndrome (Basson et al., 1997; Li et al., 1997). The identification of a 
requirement for TBX5 in cardiac cell cycle progression can therefore provide important 
insight into the cellular basis for this human disease.  However, the precise molecular 
mechanism by which TBX5 functions to promote cell proliferation within the developing 
heart awaits characterization.   
 
The maintenance of proliferating progenitor cells during early cardiogenesis
A mechanism by which proliferating cardiac progenitor cells are maintained in the 
developing heart is explored in Chapter 5.  While it is known that cardiac progenitor cells are 
induced and maintained during early development by signals including members of the FGF, 
BMP, and WNT families (Zaffran and Frasch, 2002), the exact requirement for these signals, 
especially in promoting the survival of cardiac progenitor cells, has not been well 
established.  In this work, we show that the activity SHP-2, a protein tyrosine phosphatase 
that functions downstream of receptor tyrosine kinases such as FGFR (Reviewed in (Ostman 
et al., 2006)), is required for the survival of cardiac progenitor cells. 
We have found that treatment of cardiac explants with the SHP-2 inhibitor NSC-
87877 beginning at the early neurula stage (stage 22) results in the progressive down-
regulation of early cardiac markers, and a failure of cardiac differentiation due to 
programmed cell death.  Treatment of cardiac explants with the SHP-2 inhibitor beginning at 
the late tailbud stage (stage 29) however, results in a much less severe cardiac phenotype, 
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with cardiac tissue able to undergo terminal differentiation.  Examination of cardiac cell 
proliferation revealed that the mitotic index in SHP-2 inhibited explants from stage 29 is 
reduced to approximately half of that observed in controls, indicating that proliferating 
cardiac cells require SHP-2 for their maintenance.   
At early stages of vertebrate heart development, nearly all cardiac cells are 
proliferating (Pasumarthi and Field, 2002), and these cells undergo programmed cell death in 
the absence of SHP-2 activity.  As cardiomyocytes begin to undergo differentiation, an 
increasing number of cells exit the cell cycle.  Thus, when cardiac explants are treated with 
the SHP-2 inhibitor beginning at stage 29, a much smaller subset of cells is affected than 
when treatment begins at stage 22.  This suggests that SHP-2 signaling is required 
specifically for the survival of proliferating cardiac cells.  We further show that SHP-2 likely 
functions primarily downstream of FGF signaling to promote cardiac cell survival.  
The identification of factors required for the expansion and survival of proliferating 
cardiac progenitor cells is of considerable importance both to our understanding of cardiac 
development, as well as to the generation of therapies for human cardiac diseases during 
adulthood.  Recently, several populations of multipotent cardiac progenitor cells have been 
identified, in both embryonic and neonatal mammalian hearts.  The culture of these cells 
following isolation from the heart requires the presence of growth factors, as the cells must 
be cultured in the presence of other cardiac cells or in dense clonal colonies in order to 
survive and proliferate (Laugwitz et al., 2005; Moretti et al., 2006; Wu et al., 2006).   The 
nature of the required growth factors has not been determined, however, our experiments 
point to a requirement for FGF/SHP-2/MAPK signaling in the survival of proliferating 
cardiac cells. 
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Future Directions
TBX5 and heart development 
A goal of this project in the immediate future is to further characterize the pathway in which 
TBX5 functions to regulate the cardiac cell cycle in Xenopus. We hypothesize that TBX5 is 
required for cell cycle progression non cell-autonomously. To address this, we will inject 
Xenopus embryos in one of two blastomeres at the two-cell stage with the TBX5 
Morpholinos and fluorescent dextran.  This will allow us to determine if only the cardiac 
cells directly depleted of TBX5 undergo reduced cell proliferation, or whether proliferation is 
also reduced in cardiac cells not depleted of TBX5.  If the effect is non-cell autonomous, this 
will imply that the requirement for TBX5 in cardiac cell proliferation is indirect, with TBX5 
perhaps acting upstream of growth factors to promote cell cycle progression.  If the 
requirement for TBX5 is cell autonomous, this would imply that TBX5 might directly 
regulate the transcription of genes required for G1/S transition, such as D and E cyclins, or 
Cdks 2, 4, and 6, within the developing heart. 
 Ultimately, the goal of this project is to identify direct transcriptional targets for 
TBX5.  In this way, we hope to gain further insight into the requirement for TBX5 in cell 
cycle progression, as well as to identify additional cellular requirements for TBX5.  
Currently, a number of promising approaches towards this goal are being undertaken by 
others in the lab.  These include the purification of TBX5 protein to produce an antibody, and 
the development of a proteomics-based screen to identify cardiac-specific binding partners of 
TBX5.  The production of an antibody will allow us to perform chromatin 
immunoprecipitation to identify in vivo sites at which TBX5 is bound to the DNA.  With the 
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sequencing of the Xenopus tropicalis genome, genes located in reasonable proximity to these 
binding sites can be further examined as potential transcriptional targets of TBX5.   
 As the specificity of many transcription factors is regulated, at least in part, by 
interaction with different binding partners, it is also of critical importance to identify 
additional proteins that interact with TBX5.  Thus, we are also taking a proteomics-based 
approach to identify proteins that interact with TBX5 within the heart.   His-tagged TBX5 
purified in bacteria is bound to a nickel column, and lysate either from adult heart tissue, or 
Xenopus tropicalis embryos is then put over the column.  TBX5 and any proteins bound to it 
are then eluted, and interacting proteins can be identified by mass spectroscopy. By 
identifying proteins that interact with TBX5 we can potentially identify additional cellular 
functions for TBX5, as well as gain further insight into the regulation of TBX5 during heart 
development. 
 Finally, we plan to identify upstream regulators of Tbx5 expression.  Our previous 
results have implied that expression of Tbx5 is itself dependent on the cell cycle.  Inhibiting 
the cell cycle using either aphidicolin or colchicine results in loss of expression of Tbx5 and 
other early cardiac genes, but does not affect cardiac differentiation.  We therefore 
hypothesize that, in addition to the role of TBX5 in positively regulating cell cycle 
progression in the heart, expression of Tbx5 is in turn regulated by the signaling pathways 
that control cell proliferation.  To test this, we have cloned the promoter region of Tbx5, and 
are presently taking a transgenic approach to identify the minimal region of the Tbx5 
promoter sufficient to drive expression of a GFP transgene within the developing Xenopus 
heart.  Once we identify this minimal promoter element, we will make use of available 
databases and genome sequences to identify putative transcription factor binding sites in this 
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element that are evolutionarily conserved.  We can then mutate these binding sites to 
determine whether they are required for expression of the Tbx5::GFP transgene in vivo. In 
addition, we will also perform transcriptional assays to determine whether the transcription 
factors that bind to these sites can drive expression of a Tbx5::luciferase reporter in vitro.
Initially, we will focus our analysis of putative upstream regulators of Tbx5 on transcription 
factors known to regulate cell cycle progression. 
 
Growth factors required for cardiac progenitor survival and expansion  
Having identified a requirement for the protein tyrosine phosphatase SHP-2 in the survival of 
cardiac progenitor cells, we next plan to further characterize the pathway(s) in which SHP-2 
functions during early heart development.  While we have shown that SHP-2 functions 
downstream of the FGF pathway to regulate cardiac cell survival, we hypothesize that SHP-2 
may be regulated by additional upstream pathways at different stage of development.  
Previous studies have shown that both the phosphorylation of SHP-2 at its C terminus, and its 
interaction with specific scaffolding and adaptor molecules are characteristic of the particular 
receptor tyrosine kinase functioning upstream of SHP-2.  For example, SHP-2 is 
phosphorylated at Y542 and Y580 downstream of FGF and PDGF signaling, but not 
downstream EGF or IGF (Araki et al., 2004).  In addition, SHP-2 interacts with the adaptor 
protein FRS-2 only downstream of FGFR and IGFR activation (Delahaye et al., 2000; 
Kontaridis et al., 2002; Xu et al., 1998).  Thus, by studying the phosphorylation status of 
SHP-2, and also which binding partners it associates with, we can gain information about 
which pathways are acting upstream of SHP-2 in a particular cell type.  We have shown that 
SHP-2 is phosphorylated at Y542 and Y580 and that it interacts with FRS-2 during early 
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cardiac looping stages of heart development.  We therefore plan to assess both the 
phosphorylation state of SHP-2 and interaction with FRS-2 throughout the course of cardiac 
development, to begin to determine whether SHP-2 might be regulated differently, or 
activated downstream of different pathways as heart development progresses.   
 Another approach to characterizing the pathway or pathways in which SHP-2 
functions to promote cardiac cell survival is to perform an expression screen to identify 
factors that are able to compensate for the loss of SHP-2 activity.  To do this, pooled RNAs 
will be generated from a neurula stage cDNA library, and injected into one-cell stage 
embryos.  Explants will then be cut from these embryos at the mid-neurula stage, and 
cultured in the presence of the SHP-2 inhibitor NSC-87877.  The use of a line of cardiac 
actin::GFP transgenic frogs enables us to rapidly assess whether a particular RNA pool can 
rescue the failure of cardiac differentiation that results from SHP-2 inhibition.  In this way, 
we can identify proteins required downstream of SHP-2 for the survival cardiac cells. This 
will allow us to obtain critical insight into the molecular mechanisms by which the 
maintenance and proliferation of cardiac progenitor cells are regulated during development. 
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